Lars Rydén

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Forskningsbeskrivning

Sedan 10-15 år tillbaka driver forskargruppen kring professor Lars Rydén kliniskt inriktad forskning inom området diabetes och hjärtinfarkt och har byggt upp en stor kunskapsmassa inom området.

Artiklar

Article: LAKARTIDNINGEN. 2024;121:23130

[Diabetes and periodontitis - common, important but often neglected].

Norhammar A; Gustafsson A; Rydén L; Brismar K
Article: LAKARTIDNINGEN. 2024;121:23137

[Periodontitis - an often neglected risk factor for several other diseases].

Gustafsson A; Norhammar A; Klinge B; Rydén L
Article: DIABETES CARE. 2024;47(2):S493

High Mannose Correlates With Surrogate Indexes of Insulin Resistance and Is Associated With an Increased Risk of Cardiovascular Events Independently of Glycemic Status and Traditional Risk Factors.

Fortin E; Campi B; Ferrannini E; Mari A; Mellbin LG; Norhammar A; Näsman P; Rydén L; Saba A; Ferrannini G
Article: JOURNAL OF DIABETES. 2024;16(2):e13473

Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.

Morrow LM; Becker F; Coleman RL; Gerstein HC; Rydén L; Schöder S; Gray AM; Leal J; Holman RR; ACE Study Group
Article: LAKARTIDNINGEN. 2024;121:23177

Polypiller rekommenderas av WHO för hjärt–kärlprevention.

M Nilsson P; Rydén L
Article: CARDIOVASCULAR DIABETOLOGY. 2024;23(1):25

Sex differences in the association between insulin resistance and non-fatal myocardial infarction across glycaemic states.

Riccio A; Fortin E; Mellbin L; Norhammar A; Näsman P; Rydén L; Sesti G; Ferrannini G
Article: CARDIOVASCULAR DIABETOLOGY. 2024;23(1):18

Implantable cardioverter defibrillator and cardiac resynchronization treatment in people with type 2 diabetes: a comparison with age- and sex matched controls from the general population.

Rautio E; Gadler F; Gudbjörnsdottir S; Franzén S; Rydén L; Savarese G; Svensson A-M; Mellbin LG
Article: INTERNATIONAL ENDODONTIC JOURNAL. 2024;57(1):12-22

Primary apical periodontitis correlates to elevated levels of interleukin-8 in a Swedish population: A report from the PAROKRANK study.

Sebring D; Kvist T; Lund H; Jonasson P; Lira-Junior R; Norhammar A; Rydén L; Buhlin K; EndoReCo
Article: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2024;24(1):117-127

The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.

Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH; Wang W-J; Bhatt DL; Probstfield J; Ertl G; Störk S; Steg PG; Aboyans V; Durand-Zaleski I; Ryden L; Yusuf S; COMPASS Investigators
Article: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 2023;57(1):2166101

Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial.

Ferrannini G; Maldonado JM; Raha S; Rao-Melacini P; Khatun R; Atisso C; Shurzinske L; Gerstein HC; Rydén L; Bethel MA
Article: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):208

Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia : Experiences from the randomized, controlled SOCOGAMI trial.

Fortin E; Lundin M; Mellbin L; Norhammar A; Näsman P; Smetana S; Sörensson P; Ferrannini E; Rydén L; Ferrannini G
Article: EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES. 2023;9(5):502-510

The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.

Lamy A; Eikelboom J; Tong W; Yuan F; Bangdiwala SI; Bosch J; Connolly S; Lonn E; Dagenais GR; Branch KRH; Wang W-J; Bhatt DL; Probstfield J; Ertl G; Störk S; Steg PG; Aboyans V; Durand-Zaleski I; Ryden L; Yusuf S
Article: DIABETES CARE. 2023;46(5):1046-1051

Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.

Gerstein HC; Lee S-F; Paré G; Bethel MA; Colhoun HM; Hoover A; Lakshmanan M; Lin Y; Pirro V; Qian H-R; Ruotolo G; Ryden L; Wilson JM; Duffin KL
Article: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 2022;56(1):337-342

Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANK.

Ferrannini G; Almosawi M; Buhlin K; De Faire U; Kjellström B; Klinge B; Nygren Å; Näsman P; Svenungsson E; Rydén L; Norhammar A
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2022;8(8):786-795

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.

Eikelboom JW; Bosch J; Connolly SJ; Tyrwitt J; Fox KAA; Muehlhofer E; Neumann C; Tasto C; Bangdiwala SI; Diaz R; Alings M; Dagenais GR; Leong DP; Lonn EM; Avezum A; Piegas LS; Widimsky P; Parkhomenko AN; Bhatt DL; Branch KRH; Probstfield JL; Lopez-Jaramillo P; Rydén L; Pogosova N; Keltai K; Keltai M; Ertl G; Stoerk S; Dans AL; Lanas F; Liang Y; Zhu J; Torp-Pedersen C; Maggioni AP; Commerford PJ; Guzik TJ; Vanassche T; Verhamme P; O'Donnell M; Tonkin AM; Varigos JD; Vinereanu D; Felix C; Kim J-H; Ibrahim KS; Lewis BS; Metsarinne KP; Aboyans V; Steg PG; Hori M; Kakkar A; Anand SS; Lamy A; Sharma M; Yusuf S
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2022;193:110141

SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI).

Lundin M; Ferrannini G; Mellbin L; Johansson I; Norhammar A; Näsman P; Shahim B; Smetana S; Venkateshvaran A; Wang A; Sörensson P; Rydén L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2022;24(10):1805-1812

Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.

Branch KRH; Dagenais GR; Avezum A; Basile J; Conget I; Cushman WC; Jansky P; Lakshmanan M; Lanas F; Leiter LA; Pais P; Pogosova N; Raubenheimer PJ; Ryden L; Shaw JE; Sheu WHH; Temelkova-Kurktschiev T; Bethel MA; Gerstein HC; Chinthanie R; Probstfield JL
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):195

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study.

Fortin E; Ferrannini G; Campi B; Mellbin L; Norhammar A; Näsman P; Saba A; Ferrannini E; Rydén L
Article: DIABETES CARE. 2022;45(9):2111-2117

Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V Population.

Ferrannini G; De Bacquer D; Erlund I; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Schnell O; Tuomilehto J; Vihervaara T; Wood D; Rydén L
Article: EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES. 2022;8(5):568-576

Potential for optimizing management of obesity in the secondary prevention of coronary heart disease.

De Bacquer D; Jennings CS; Mirrakhimov E; Lovic D; Bruthans J; De Smedt D; Gotcheva N; Dolzhenko M; Fras Z; Pogosova N; Lehto S; Hasan-Ali H; Jankowski P; Kotseva K; De Backer G; Wood D; Rydén L
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2022;107(8):e3448-e3454

Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.

Cukierman-Yaffe T; Gerstein HC; Basile J; Bethel MA; Cardona-Muñoz EG; Conget I; Dagenais G; Franek E; Hall S; Hancu N; Jansky P; Lakshmanan M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Probstfield J; Rao-Melacini P; Ramasundarahettige C; Raubenheimer PJ; Riddle MC; Rydén L; Shaw JE; Sheu WH-H; Temelkova-Kurktschiev T
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):129

Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort.

Meziani S; Ferrannini G; Bjerre M; Hansen TK; Ritsinger V; Norhammar A; Gyberg V; Näsman P; Rydén L; Mellbin LG
Article: DIABETES OBESITY & METABOLISM. 2022;24(4):704-712

Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.

Raubenheimer PJ; Cushman WC; Avezum A; Basile J; Conget I; Dagenais G; Hoover A; Jansky P; Lanas F; Leiter LA; Lopez-Jaramillo P; Pogosova N; Probstfield J; Rao-Melacini P; Rydén L; Sheu WH-H; Temelkova-Kurktschiev T; C Gerstein H
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;29(2):383-395

Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys.

De Bacquer D; Astin F; Kotseva K; Pogosova N; De Smedt D; De Backer G; Rydén L; Wood D; Jennings C; EUROASPIRE IV and V surveys of the European Observ
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;29(2):344-351

Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry.

Vynckier P; Ferrannini G; Rydén L; Jankowski P; De Backer T; Gevaert S; De Bacquer D; De Smedt D; EUROASPIRE V Investigators group
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;29(2):328-339

Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model.

De Bacquer D; Ueda P; Reiner Ž; De Sutter J; De Smedt D; Lovic D; Gotcheva N; Fras Z; Pogosova N; Mirrakhimov E; Lehto S; Jernberg T; Kotseva K; Rydén L; Wood D; De Backer G; EUROASPIRE IV and V National Coordinators
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2022;183:109156

Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test: Validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registry.

Ferrannini G; De Bacquer D; Gyberg V; De Backer G; Kotseva K; Mellbin LG; Risebrink R; Tuomilehto J; Wood D; Rydén L
Article: INTERNATIONAL ENDODONTIC JOURNAL. 2022;55(1):6-17

Endodontic inflammatory disease: A risk indicator for a first myocardial infarction.

Sebring D; Buhlin K; Norhammar A; Rydén L; Jonasson P; EndoReCo; Lund H; Kvist T
Article: ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY. 2022;133(1):88-99

Association of high cardiovascular risk and diabetes with calcified carotid artery atheromas depicted on panoramic radiographs.

Gustafsson N; Ahlqvist J; Norhammar A; Näslund U; Rydén L; Wester P; Levring Jäghagen E
Article: EUROPEAN HEART JOURNAL OPEN. 2021;1(2):oeab023

Androgen receptor polymorphism, testosterone levels, and prognosis in patients with acute myocardial infarction.

Wang A; Flanagan J; Arver S; Norhammar A; Näsman P; Rydén L; Mellbin LG
Article: LANCET DIABETES & ENDOCRINOLOGY. 2021;9(8):484-490

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.

Bajaj HS; Gerstein HC; Rao-Melacini P; Basile J; Colhoun H; Conget I; Cushman WC; Dagenais GR; Franek E; Hanefeld M; Keltai M; Lakshmanan M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Probstfield J; Raubenheimer P; Ryden L; Shaw JE; Sheu WH-H; Xavier D
Article: DRUGS. 2021;81(12):1373-1379

Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care.

Jacob S; Krentz AJ; Deanfield J; Rydén L
Article: CARDIOVASCULAR DRUGS AND THERAPY. 2021;35(4):801-808

Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry.

Vynckier P; Ferrannini G; Rydén L; Tokgözoğlu L; Bruthans J; Kotseva K; Wood D; De Backer T; Gevaert S; De Bacquer D; De Smedt D; EUROASPIRE V Investigators group
Article: EUROPEAN HEART JOURNAL. 2021;42(26):2565-2573

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.

Ferrannini G; Gerstein H; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probstfield J; Riddle MC; Shaw JE; Avezum A; Basile JN; Cushman WC; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pais P; Pīrāgs V; Pogosova N; Raubenheimer PJ; Sheu WH-H; Rydén L
Article: DIABETES OBESITY & METABOLISM. 2021;23(7):1677-1680

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.

Verma S; Fainberg U; Husain M; Rasmussen S; Rydén L; Ripa MS; Buse JB
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2021;51(7):e13516

Copeptin is associated with mortality in elderly people.

Smaradottir MI; Andersen K; Gudnason V; Näsman P; Rydén L; Mellbin LG
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2021;28(4):370-379

Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.

Kotseva K; De Backer G; De Bacquer D; Rydén L; Hoes A; Grobbee D; Maggioni A; Marques-Vidal P; Jennings C; Abreu A; Aguiar C; Badariene J; Bruthans J; Cifkova R; Davletov K; Dilic M; Dolzhenko M; Gaita D; Gotcheva N; Hasan-Ali H; Jankowski P; Lionis C; Mancas S; Milićić D; Mirrakhimov E; Oganov R; Pogosova N; Reiner Ž; Vulić D; Wood D; EUROASPIRE V Investigators
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2021;175:108819

The history of the Nobel prize for the discovery of insulin.

Rydén L; Lindsten J
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2021;175:108796

Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.

Ferrannini G; Savarese G; Rydén L
Article: LAKARTIDNINGEN. 2021;118:20214

Stöd för effekt av polypiller i kardiovaskulär prevention.

M Nilsson P; Rydén L
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2021;18(2):14791641211002475-147916412110024

Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial.

Wang A; Gerstein HC; Lee SF; Hess S; Paré G; Rydén L; Mellbin LG
Article: CARDIOVASCULAR DIABETOLOGY. 2021;20(1):38

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys.

Ferrannini G; De Bacquer D; Vynckier P; De Backer G; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Tuomilehto J; Wood D; Rydén L; EUROASPIRE IV & V Investigators
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2021;322:227-232

Peripheral arterial disease and intermittent claudication in coronary heart disease patients.

Reiner Ž; De Sutter J; Ryden L; Mirrakhimov E; Pogosova N; Dolzhenko M; Fras Z; Kotseva K; Wood D; De Bacquer D
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2020;170:108488

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.

Wamil M; McMurray JJV; Scott CAB; Coleman RL; Sun Y; Standl E; Rydén L; Holman RR
Article: CARDIOVASCULAR DIABETOLOGY. 2020;19(1):199

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.

Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
Article: DIABETES CARE. 2020;43(11):2853-2858

Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population.

Rautio E; Gadler F; Gudbjörnsdottir S; Franzén S; Rydén L; Svensson A-M; Mellbin LG
Article: STROKE. 2020;51(10):2901-2909

Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.

Sharma M; Hart RG; Smith EE; Bosch J; Eikelboom JW; Connolly SJ; Dyal L; Reeh KW; Casanova A; Diaz R; Lopez-Jaramillo P; Ertl G; Störk S; Dagenais GR; Lonn EM; Ryden L; Tonkin AM; Varigos JD; Bhatt DL; Branch KRH; Probstfield JL; Kim J-H; O'Donnell M; Vinereanu D; A A Fox K; Liang Y; Liu L; Zhu J; Pogosova N; Maggioni AP; Avezum A; Piegas LS; Keltai K; Keltai M; Berkowitz SD; Yusuf S
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2020;27(15):1630-1636

Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study.

Bacquer DD; Smedt DD; Reiner Ž; Tokgözoğlu L; Clays E; Kotseva K; Rydén L; Wood D; Backer GD
Article: DIABETES CARE. 2020;43(9):2001-2009

Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management.

Ferrannini G; Norhammar A; Gyberg V; Mellbin L; Rydén L
Article: DIABETES CARE. 2020;43(9):2242-2247

Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.

Gerstein HC; Coleman RL; Scott CAB; Xu S; Tuomilehto J; Rydén L; Holman RR; ACE Study Group
Article: LANCET NEUROLOGY. 2020;19(7):582-590

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.

Cukierman-Yaffe T; Gerstein HC; Colhoun HM; Diaz R; García-Pérez L-E; Lakshmanan M; Bethel A; Xavier D; Probstfield J; Riddle MC; Rydén L; Atisso CM; Hall S; Rao-Melacini P; Basile J; Cushman WC; Franek E; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH-H; Temelkova-Kurktschiev T
Article: CIRCULATION. 2020;141(23):1841-1854

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.

Bhatt DL; Eikelboom JW; Connolly SJ; Steg PG; Anand SS; Verma S; Branch KRH; Probstfield J; Bosch J; Shestakovska O; Szarek M; Maggioni AP; Widimský P; Avezum A; Diaz R; Lewis BS; Berkowitz SD; Fox KAA; Ryden L; Yusuf S; COMPASS Steering Committee and Investigators
Article: DIABETES CARE. 2020;43(4):726-733

Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V.

Ferrannini G; De Bacquer D; De Backer G; Kotseva K; Mellbin L; Wood D; Rydén L; EUROASPIRE V collaborators
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2020;17(3):1479164120922123-147916412092212

Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?

Ferrannini G; Svenungsson E; Kjellström B; Elvin K; Grosso G; Näsman P; Rydén L; Norhammar A
Article: LANCET DIABETES & ENDOCRINOLOGY. 2020;8(2):106-114

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.

Gerstein HC; Hart R; Colhoun HM; Diaz R; Lakshmanan M; Botros FT; Probstfield J; Riddle MC; Rydén L; Atisso CM; Dyal L; Hall S; Avezum A; Basile J; Conget I; Cushman WC; Hancu N; Hanefeld M; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Muñoz EGC; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH-H; Temelkova-Kurktschiev T
Article: JOURNAL OF DENTAL RESEARCH. 2020;99(1):60-68

Associations among Periodontitis, Calcified Carotid Artery Atheromas, and Risk of Myocardial Infarction.

Gustafsson N; Ahlqvist J; Näslund U; Buhlin K; Gustafsson A; Kjellström B; Klinge B; Rydén L; Levring Jäghagen E
Article: DIABETES STOFFWECHSEL UND HERZ. 2020;29(3):164-170

Proceedings of the Guideline Workshop 2019-Strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases

Marx N; Ryden L; Brosius F; Ceriello A; Cheung M; Cosentino F; Green J; Kellerer M; Koob S; Kosiborod M; Nedungadi P; Rodbard HW; Vandvik PO; Standl E; Schnell O
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(2_suppl):73-80

Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.

Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(2_suppl):33-46

The metabolic syndrome - What is it and how should it be managed?

Nilsson PM; Tuomilehto J; Rydén L
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(2_suppl):47-54

Risk and management of pre-diabetes.

Beulens J; Rutters F; Rydén L; Schnell O; Mellbin L; Hart HE; Vos RC
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(2_suppl):81-91

Risk factor reduction in type 2 diabetes demands a multifactorial approach.

Rydén L; Ferrannini G; Mellbin L
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(2_suppl):25-32

Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications.

Dal Canto E; Ceriello A; Rydén L; Ferrini M; Hansen TB; Schnell O; Standl E; Beulens JW
Article: CIRCULATION. 2019;140(18):1451-1459

Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.

Eikelboom JW; Connolly SJ; Bosch J; Shestakovska O; Aboyans V; Alings M; Anand SS; Avezum A; Berkowitz SD; Bhatt DL; Cook-Bruns N; Felix C; Fox KAA; Hart RG; Maggioni AP; Moayyedi P; O'Donnell M; Rydén L; Verhamme P; Widimsky P; Zhu J; Yusuf S
Article: EUROPEAN HEART JOURNAL. 2019;40(34):2907-2919

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.

Cosentino F; Ceriello A; Baeres FMM; Fioretto P; Garber A; Stough WG; George JT; Grant PJ; Khunti K; Langkilde AM; Plutzky J; Rydén L; Scheen A; Standl E; Tuomilehto J; Zannad F
Article: GASTROENTEROLOGY. 2019;157(3):682-691.e2

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Bruns NC; Muehlhofer E; Dagenais GR; Kim J-H; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar AK; Parkhomenko AN; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne KP; Fox KAA; Yusuf S; COMPASS Investigators
Article: DIABETES CARE. 2019;42(8):1504-1511

Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study.

Norhammar A; Kjellström B; Habib N; Gustafsson A; Klinge B; Nygren Å; Näsman P; Svenungsson E; Rydén L
Article: GASTROENTEROLOGY. 2019;157(2):403-412.e5

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.

Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Cook Bruns N; Muehlhofer E; Dagenais GR; Kim J-H; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar A; Parkhomenko AN; Ryden L; Pogosova N; Dans A; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik T; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne K; Fox KAA; Yusuf S; COMPASS Investigators
Article: LANCET. 2019;394(10193):121-130

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riesmeyer JS; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH-H; Temelkova-Kurktschiev T; REWIND Investigators
Article: LANCET. 2019;394(10193):131-138

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Botros FT; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH-H; Temelkova-Kurktschiev T; REWIND Investigators
Article: ATHEROSCLEROSIS. 2019;285:135-146

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries.

De Backer G; Jankowski P; Kotseva K; Mirrakhimov E; Reiner Ž; Rydén L; Tokgözoğlu L; Wood D; De Bacquer D; EUROASPIRE V collaborators; Writing Committee; Scientific Steering/ Executive Committee; Coordinating centre; Diabetes centre; Data management centre; Statistical analysis centre; Central laboratory; Study centres, organisations, investigators and ot
Article: ACTA ODONTOLOGICA SCANDINAVICA. 2019;77(4):282-289

Attitudes and lifestyle factors in relation to oral health and dental care in Sweden: a cross-sectional study.

Naimi-Akbar A; Kjellström B; Rydén L; Rathnayake N; Klinge B; Gustafsson A; Buhlin K
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(8):847-854

Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial.

Wang A; Arver S; Boman K; Gerstein HC; Fu Lee S; Hess S; Rydén L; Mellbin LG
Article: HERZ. 2019;44(3):192-202

Clinical implications of cardiovascular outcome trials in type 2 diabetes.

Mellbin LG; Wang A; Rydén L
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(8):824-835

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.

Kotseva K; De Backer G; De Bacquer D; Rydén L; Hoes A; Grobbee D; Maggioni A; Marques-Vidal P; Jennings C; Abreu A; Aguiar C; Badariene J; Bruthans J; Castro Conde A; Cifkova R; Crowley J; Davletov K; Deckers J; De Smedt D; De Sutter J; Dilic M; Dolzhenko M; Dzerve V; Erglis A; Fras Z; Gaita D; Gotcheva N; Heuschmann P; Hasan-Ali H; Jankowski P; Lalic N; Lehto S; Lovic D; Mancas S; Mellbin L; Milicic D; Mirrakhimov E; Oganov R; Pogosova N; Reiner Z; Stöerk S; Tokgözoğlu L; Tsioufis C; Vulic D; Wood D; EUROASPIRE Investigators*
Article: INTERNATIONAL JOURNAL OF STROKE. 2019;14(3):270-281

Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.

Sharma M; Hart RG; Smith EE; Bosch J; Yuan F; Casanova A; Eikelboom JW; Connolly SJ; Wong G; Diaz R; Lopez-Jaramillo P; Ertl G; Störk S; Dagenais GR; Lonn EM; Ryden L; Tonkin AM; Varigos JD; Bhatt DL; Branch KR; Probstfield JL; Kim J-H; Ha J-W; O'Donnell M; Vinereanu D; Fox KA; Liang Y; Liu L; Zhu J; Pogosova N; Maggioni AP; Avezum A; Piegas LS; Keltai K; Keltai M; Cook Bruns N; Berkowitz S; Yusuf S
Article: EUROPEAN JOURNAL OF EPIDEMIOLOGY. 2019;34(3):247-258

Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study.

De Bacquer D; De Smedt D; Kotseva K; Jennings C; Wood D; Rydén L; Gyberg V; Shahim B; Amouyel P; Bruthans J; Castro Conde A; Cífková R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pajak A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D; Wagner M; De Backer G; EUROASPIRE Investigators
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2018;25(18):1990-1999

Effectiveness of different outreach strategies to identify individuals at high risk of diabetes in a heterogeneous population: a study in the Swedish municipality of Södertälje.

Shahim B; Hasselberg S; Boldt-Christmas O; Gyberg V; Mellbin L; Rydén L
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2018;272:20-25

Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey.

De Smedt D; Annemans L; De Backer G; Kotseva K; Rydèn L; Wood D; Amouyel P; Bruthans J; Cifkova R; De Sutter J; Dolzhenko M; Erglis A; Gotcheva N; Gyberg V; Laucevicius A; Lovic D; Oganov R; Pajak A; Pogosova N; Reiner Ž; Stagmo M; De Bacquer D
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2018;15(6):494-503

Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function.

Johansson I; Dahlström U; Edner M; Näsman P; Rydén L; Norhammar A
Article: JOURNAL OF DENTAL RESEARCH. 2018;97(10):1114-1121

Severe Periodontitis Is Associated with Myocardial Infarction in Females.

Nordendahl E; Gustafsson A; Norhammar A; Näsman P; Rydén L; Kjellström B; PAROKRANK Steering Committee
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2018;15(5):387-395

Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort.

Ritsinger V; Brismar K; Mellbin L; Näsman P; Rydén L; Söderberg S; Norhammar A
Article: DIABETES TECHNOLOGY & THERAPEUTICS. 2018;20(9):596-602

The Accuracy of Point-of-Care Equipment for Glucose Measurement in Screening for Dysglycemia in Patients with Coronary Artery Disease.

Shahim B; Kjellström B; Gyberg V; Jennings C; Smetana S; Rydén L
Article: DIABETES CARE. 2018;41(8):1792-1800

Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.

Schrieks IC; Nozza A; Stähli BE; Buse JB; Henry RR; Malmberg K; Neal B; Nicholls SJ; Rydén L; Mellbin L; Svensson A; Wedel H; Weichert A; Lincoff AM; Tardif J-C; Grobbee DE; Schwartz GG
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2018;103(7):2522-2533

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.

Stähli BE; Nozza A; Schrieks IC; Buse JB; Malmberg K; Mellbin L; Neal B; Nicholls SJ; Rydén L; Svensson A; Wedel H; Weichert A; Lincoff AM; Grobbee DE; Tardif J-C; Schwartz GG
Article: AMERICAN HEART JOURNAL. 2018;199:170-175

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.

Theodorakis MJ; Coleman RL; Feng H; Chan J; Chiasson J-L; Ge J; Gerstein HC; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Tendera M; Tuomilehto J; Yang W; Hu D; Pan C; Holman RR; ACE Study Group
Article: CARDIOVASCULAR DIABETOLOGY. 2018;17(1):21

Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology.

Shahim B; Gyberg V; De Bacquer D; Kotseva K; De Backer G; Schnell O; Tuomilehto J; Wood D; Rydén L
Article: LANCET. 2018;391(10117):219-229

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.

Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S; COMPASS Investigators
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2018;15(1):14-23

Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.

Savonitto S; Morici N; Nozza A; Cosentino F; Perrone Filardi P; Murena E; Morocutti G; Ferri M; Cavallini C; Eijkemans MJ; Stähli BE; Schrieks IC; Toyama T; Lambers Heerspink HJ; Malmberg K; Schwartz GG; Lincoff AM; Ryden L; Tardif JC; Grobbee DE
Article: DIABETES OBESITY & METABOLISM. 2018;20(1):42-49

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.

Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riddle MC; Rydén L; Xavier D; Atisso CM; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona-Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw J; Sheu WH-H; Temelkova-Kurktschiev T; REWIND Trial Investigators
Article: CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING. 2018;38(1):118-127

Effects of enhanced external counterpulsation on skeletal muscle gene expression in patients with severe heart failure.

Melin M; Montelius A; Rydén L; Gonon A; Hagerman I; Rullman E
Article: GLOBAL HEART. 2017;12(4):315-322.e3

Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013.

Kotseva K; De Bacquer D; Jennings C; Gyberg V; De Backer G; Rydén L; Amouyel P; Bruthans J; Cifkova R; Deckers JW; De Sutter J; Fraz Z; Graham I; Keber I; Lehto S; Moore D; Pajak A; Wood D; EUROASPIRE Investigators
Article: LANCET DIABETES & ENDOCRINOLOGY. 2017;5(11):877-886

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Holman RR; Coleman RL; Chan JCN; Chiasson J-L; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C; ACE Study Group
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2017;377(14):1319-1330

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Eikelboom JW; Connolly SJ; Bosch J; Dagenais GR; Hart RG; Shestakovska O; Diaz R; Alings M; Lonn EM; Anand SS; Widimsky P; Hori M; Avezum A; Piegas LS; Branch KRH; Probstfield J; Bhatt DL; Zhu J; Liang Y; Maggioni AP; Lopez-Jaramillo P; O'Donnell M; Kakkar AK; Fox KAA; Parkhomenko AN; Ertl G; Störk S; Keltai M; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Verhamme PB; Vinereanu D; Kim J-H; Tonkin AM; Lewis BS; Felix C; Yusoff K; Steg PG; Metsarinne KP; Cook Bruns N; Misselwitz F; Chen E; Leong D; Yusuf S; COMPASS Investigators
Article: DIABETES CARE. 2017;40(9):1233-1240

The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology.

Shahim B; De Bacquer D; De Backer G; Gyberg V; Kotseva K; Mellbin L; Schnell O; Tuomilehto J; Wood D; Rydén L
Article: CANADIAN JOURNAL OF CARDIOLOGY. 2017;33(8):1027-1035

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

Bosch J; Eikelboom JW; Connolly SJ; Bruns NC; Lanius V; Yuan F; Misselwitz F; Chen E; Diaz R; Alings M; Lonn EM; Widimsky P; Hori M; Avezum A; Piegas LS; Bhatt DL; Branch KRH; Probstfield JL; Liang Y; Liu L; Zhu J; Maggioni AP; Lopez-Jaramillo P; O'Donnell M; Fox KAA; Kakkar A; Parkhomenko AN; Ertl G; Störk S; Keltai K; Keltai M; Ryden L; Dagenais GR; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Verhamme PB; Vinereanu D; Kim J-H; Ha J-W; Tonkin AM; Varigos JD; Lewis BS; Felix C; Yusoff K; Steg PG; Aboyans V; Metsarinne KP; Anand SS; Hart RG; Lamy A; Moayyedi P; Leong DP; Sharma M; Yusuf S
Article: EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING. 2017;16(6):468-474

Symptoms of depression and their relation to myocardial infarction and periodontitis.

Kjellström B; Gustafsson A; Nordendal E; Norhammar A; Nygren Å; Näsman P; Rydén L; Åsberg M; PAROKRANK steering committee
Article: JOURNAL OF CLINICAL PERIODONTOLOGY. 2017;44(7):692-699

Saliva and plasma levels of cardiac-related biomarkers in post-myocardial infarction patients.

Rathnayake N; Buhlin K; Kjellström B; Klinge B; Löwbeer C; Norhammar A; Rydén L; Sorsa T; Tervahartiala T; Gustafsson A; PAROKRANK Steering Committee
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2017;24(11):1168-1180

Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: Insights from the EUROASPIRE IV survey of the European Society of Cardiology.

Wagner M; Wanner C; Kotseva K; Wood D; De Bacquer D; Rydén L; Störk S; Heuschmann PU; EUROASPIRE IV investigators
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2017;24(8):858-866

The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.

van Steen SC; Schrieks IC; Hoekstra JB; Lincoff AM; Tardif J-C; Mellbin LG; Rydén L; Grobbee DE; DeVries JH; AleCardio study group
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2017;14(2):77-87

Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort.

Ritsinger V; Brismar K; Malmberg K; Mellbin L; Näsman P; Rydén L; Söderberg S; Tenerz Å; Norhammar A
Article: BMJ OPEN. 2016;6(12):e013835

Time-saving screening for diabetes in patients with coronary artery disease: a report from EUROASPIRE IV.

Gyberg V; De Bacquer D; Kotseva K; De Backer G; Schnell O; Tuomilehto J; Wood D; Rydén L
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2016;23(18):2007-2018

Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions.

Kotseva K; De Bacquer D; De Backer G; Rydén L; Jennings C; Gyberg V; Abreu A; Aguiar C; Conde AC; Davletov K; Dilic M; Dolzhenko M; Gaita D; Georgiev B; Gotcheva N; Lalic N; Laucevicius A; Lovic D; Mancas S; Miličić D; Oganov R; Pajak A; Pogosova N; Reiner Ž; Vulic D; Wood D; On Behalf Of The Euroaspire Investigators
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2016;23(15):1618-1627

Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys.

De Backer G; De Bacquer D; Rydén L; Kotseva K; Gaita D; Georgiev B; Gotcheva N; Mancas S; Miličić D; Pająk A; Reiner Ž; Wood D; EUROASPIRE investigators
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2016;220:750-758

Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF).

Makubi A; Hage C; Sartipy U; Lwakatare J; Janabi M; Kisenge P; Dahlström U; Rydén L; Makani J; Lund LH
Article: CARDIOVASCULAR DIABETOLOGY. 2016;15(1):139

Current perspectives on cardiovascular outcome trials in diabetes.

Schnell O; Rydén L; Standl E; Ceriello A; D&CVD EASD Study Group
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2016;68(13):1404-1416

Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure.

Johansson I; Dahlström U; Edner M; Näsman P; Rydén L; Norhammar A
Article: EXPERT REVIEW OF CARDIOVASCULAR THERAPY. 2016;14(9):987-989

Periodontal disease - important to consider in cardiovascular disease prevention.

Kjellström B; Rydén L; Klinge B; Norhammar A
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2016;13(4):307-311

Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study.

Arnetz L; Hage C; Brismar K; Catrina S-B; Norhammar A; Lundman P; Wallander M; Ryden L; Mellbin L
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2016;23(6):636-648

EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.

Kotseva K; Wood D; De Bacquer D; De Backer G; Rydén L; Jennings C; Gyberg V; Amouyel P; Bruthans J; Castro Conde A; Cífková R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pajak A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D; EUROASPIRE Investigators
Article: CIRCULATION. 2016;133(6):576-583

Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study.

Rydén L; Buhlin K; Ekstrand E; de Faire U; Gustafsson A; Holmer J; Kjellström B; Lindahl B; Norhammar A; Nygren Å; Näsman P; Rathnayake N; Svenungsson E; Klinge B
Article: DIABETES TECHNOLOGY & THERAPEUTICS. 2015;17(10):755-758

Accuracy of a Simplified Glucose Measurement Device--The HemoCue Glucose 201RT.

Segerhag E; Gyberg V; Ioannides K; Jennings C; Rydén L; Stagmo M; Hage C
Article: CARDIOVASCULAR DIABETOLOGY. 2015;14:133

Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology.

Gyberg V; De Bacquer D; De Backer G; Jennings C; Kotseva K; Mellbin L; Schnell O; Tuomilehto J; Wood D; Rydén L; Amouyel P; Bruthans J; Conde AC; Cifkova R; Deckers JW; De Sutter J; Dilic M; Dolzhenko M; Erglis A; Fras Z; Gaita D; Gotcheva N; Goudevenos J; Heuschmann P; Laucevicius A; Lehto S; Lovic D; Miličić D; Moore D; Nicolaides E; Oganov R; Pająk A; Pogosova N; Reiner Z; Stagmo M; Störk S; Tokgözoğlu L; Vulic D; EUROASPIRE Investigators
Article: HEART. 2015;101(14):1139-1148

Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes.

Johansson I; Dahlström U; Edner M; Näsman P; Rydén L; Norhammar A
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2015;22(6):753-761

Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study.

Gyberg V; Kotseva K; Dallongeville J; Backer GD; Mellbin L; Rydén L; Wood D; Bacquer DD; EUROASPIRE Study Group
Article: EUROPEAN HEART JOURNAL. 2015;36(19):1171-1177

Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology.

Gyberg V; De Bacquer D; Kotseva K; De Backer G; Schnell O; Sundvall J; Tuomilehto J; Wood D; Rydén L; EUROASPIRE IV Investigators
Article: HEART. 2015;101(8):592-599

Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure.

Makubi A; Hage C; Lwakatare J; Mmbando B; Kisenge P; Lund LH; Rydén L; Makani J
Article: PLOS ONE. 2015;10(7):e0126370

Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to Coronary Artery Disease).

Rathnayake N; Gustafsson A; Norhammar A; Kjellström B; Klinge B; Rydén L; Tervahartiala T; Sorsa T; PAROKRANK Steering Group
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2015;12(1):23-32

Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort.

Ritsinger V; Tanoglidi E; Malmberg K; Näsman P; Rydén L; Tenerz Å; Norhammar A
Article: DIABETES CARE. 2014;37(11):3092-3097

Longitudinal development of left ventricular diastolic function in patients with type 2 diabetes.

Venskutonyte L; Jarnert C; Rydén L; Kjellström B
Article: HEART. 2014;100(16):1235-1241

Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study.

Makubi A; Hage C; Lwakatare J; Kisenge P; Makani J; Rydén L; Lund LH
Article: LANCET DIABETES & ENDOCRINOLOGY. 2014;2(8):627-633

Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.

Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2014;21(7):813-822

SURF - SUrvey of Risk Factor management: first report of an international audit.

Cooney M; Reiner Z; Sheu W; Ryden L; Sutter JD; De Bacquer D; DeBacker G; Mithal A; Chung N; Lim Y; Dudina A; Reynolds A; Dunney K; Graham I; SURF investigators; Prevention, Epidemiology and Population Science Se
Article: AMERICAN HEART JOURNAL. 2014;168(1):23-9.e2

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

Holman RR; Bethel MA; Chan JCN; Chiasson J-L; Doran Z; Ge J; Gerstein H; Huo Y; McMurray JJ; Ryden L; Liyanage W; Schröder S; Tendera M; Theodorakis MJ; Tuomilehto J; Yang W; Hu D; Pan C; ACE Study Group
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2014;11(4):290-293

The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study.

Hage C; Brismar K; Lundman P; Norhammar A; Rydén L; Mellbin L
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2014;11(3):133-173

ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary.

Task Force on diabetes, pre-diabetes, and cardiova; European Association for the Study of Diabetes (EA; Rydén L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes H-P; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Uva MS; Taskinen M-R; Tendera M; Tuomilehto J; Valensi P; Zamorano JL
Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2014;311(15):1515-1525

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM; Tardif J-C; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE; AleCardio Investigators
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2014;16(4):409-418

Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry.

Johansson I; Edner M; Dahlström U; Näsman P; Rydén L; Norhammar A
Article: PLOS ONE. 2014;9(12):e113740

Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls.

Mohammad A-A; Rahbar A; Lui W-O; Davoudi B; Catrina A; Stragliotto G; Mellbin L; Hamsten A; Rydén L; Yaiw K-C; Söderberg-Nauclér C
Article: JOURNAL OF INTERNAL MEDICINE. 2013;274(6):529-540

Early achievements in cardiovascular care as reflected in the Journal of Internal Medicine.

Rydén L
Article: EUROPEAN HEART JOURNAL. 2013;34(40):3137-3144

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.

ORIGIN Trial Investigators; Mellbin LG; Rydén L; Riddle MC; Probstfield J; Rosenstock J; Díaz R; Yusuf S; Gerstein HC
Article: EUROPEAN HEART JOURNAL. 2013;34(39):3035-3087

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).

Authors/Task Force Members; Rydén L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes H-P; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Uva MS; Taskinen M-R; Tendera M; Tuomilehto J; Valensi P; Zamorano JL; ESC Committee for Practice Guidelines (CPG); Zamorano JL; Achenbach S; Baumgartner H; Bax JJ; Bueno H; Dean V; Deaton C; Erol C; Fagard R; Ferrari R; Hasdai D; Hoes AW; Kirchhof P; Knuuti J; Kolh P; Lancellotti P; Linhart A; Nihoyannopoulos P; Piepoli MF; Ponikowski P; Sirnes PA; Tamargo JL; Tendera M; Torbicki A; Wijns W; Windecker S; Document Reviewers; De Backer G; Sirnes PA; Ezquerra EA; Avogaro A; Badimon L; Baranova E; Baumgartner H; Betteridge J; Ceriello A; Fagard R; Funck-Brentano C; Gulba DC; Hasdai D; Hoes AW; Kjekshus JK; Knuuti J; Kolh P; Lev E; Mueller C; Neyses L; Nilsson PM; Perk J; Ponikowski P; Reiner Z; Sattar N; Schächinger V; Scheen A; Schirmer H; Strömberg A; Sudzhaeva S; Tamargo JL; Viigimaa M; Vlachopoulos C; Xuereb RG
Article: DIABETES CARE. 2013;36(9):2466-2474

Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE).

Lonn EM; Bosch J; Diaz R; Lopez-Jaramillo P; Ramachandran A; Hâncu N; Hanefeld M; Krum H; Ryden L; Smith S; McQueen MJ; Dyal L; Yusuf S; Gerstein HC; GRACE and ORIGIN Investigators
Article: AMERICAN HEART JOURNAL. 2013;166(3):429-434

Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

Lincoff AM; Tardif J-C; Neal B; Nicholls SJ; Rydén L; Schwartz GG; Malmberg K; Buse JB; Henry RR; Wedel H; Weichert A; Cannata R; Grobbee DE
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2013;20(4):549-554

Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes.

Hage C; Lundman P; Rydén L; Mellbin L
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2013;10(4):361-367

Self-rated health predicts outcome in patients with type 2 diabetes and myocardial infarction: a DIGAMI 2 quality of life sub-study.

Venskutonyte L; Brismar K; Öhrvik J; Rydén L; Kjellström B
Article: JOURNAL OF HYPERTENSION. 2013;31(7):1281-1357

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Mancia G; Fagard R; Narkiewicz K; Redón J; Zanchetti A; Böhm M; Christiaens T; Cifkova R; De Backer G; Dominiczak A; Galderisi M; Grobbee DE; Jaarsma T; Kirchhof P; Kjeldsen SE; Laurent S; Manolis AJ; Nilsson PM; Ruilope LM; Schmieder RE; Sirnes PA; Sleight P; Viigimaa M; Waeber B; Zannad F; Task Force Members
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2013;10(3):263-269

Satisfaction with glucose-lowering treatment and well-being in patients with type 2 diabetes and myocardial infarction: a DIGAMI2 QoL sub-study.

Venskutonyte L; Brismar K; Rydén-Bergsten T; Rydén L; Kjellström B
Article: JOURNAL OF INTERNAL MEDICINE. 2013;273(4):410-421

Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.

Hage C; Brismar K; Efendic S; Lundman P; Rydén L; Mellbin L
Article: BMC CARDIOVASCULAR DISORDERS. 2013;13:22

Long-term impact of postconditioning on infarct size and left ventricular ejection fraction in patients with ST-elevation myocardial infarction.

Sörensson P; Rydén L; Saleh N; Tornvall P; Arheden H; Pernow J
Article: JOURNAL OF HYPERTENSION. 2013;31(2):414-421

Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial.

Mann JFE; Anderson C; Gao P; Gerstein HC; Boehm M; Rydén L; Sleight P; Teo KK; Yusuf S; ONTARGET investigators
Article: EUROPEAN HEART JOURNAL. 2013;34(5):374-379

The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial.

Mellbin LG; Malmberg K; Rydén L; Wedel H; Vestberg D; Lind M
Article: KARDIOLOGIA POLSKA. 2013;71 Suppl 11:S319-S394

[ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD].

Grupa Robocza Europejskiego Towarzystwa Kardiologi; Rydén L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes H-P; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Sousa Uva M; Taskinen M-R; Tendera M; Tuomilehto J; Valensi P; Zamorano JL; European Association for the Study of Diabetes (EA
Article: INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE. 2012;19(4):403-488

European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Perk J; De Backer G; Gohlke H; Graham I; Reiner Z; Verschuren WMM; Albus C; Benlian P; Boysen G; Cifkova R; Deaton C; Ebrahim S; Fisher M; Germano G; Hobbs R; Hoes A; Karadeniz S; Mezzani A; Prescott E; Ryden L; Scherer M; Syvänne M; Op Reimer WJMS; Vrints C; Wood D; Zamorano JL; Zannad F; European Association for Cardiovascular Prevention
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2012;9(4):287-295

Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.

Jarnert C; Kalani M; Rydén L; Böhm F
Article: CURRENT VASCULAR PHARMACOLOGY. 2012;10(6):690-692

Joint ESC/EASD guidelines on diabetes, where are we now and where should we go?

Rydén L; Mellbin L
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2012;19(4):585-667

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Fifth Joint Task Force of the European Society of ; European Association of Echocardiography; European Association of Percutaneous Cardiovascula; European Heart Rhythm Association; Heart Failure Association; European Association for Cardiovascular Prevention; European Atherosclerosis Society; International Society of Behavioural Medicine; European Stroke Organisation; European Society of Hypertension; European Association for the Study of Diabetes; European Society of General Practice/Family Medici; International Diabetes Federation Europe; European Heart Network
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2012;9(3):226-233

Mortality prediction in the elderly by an easily measured metabolic index.

Venskutonyte L; Rydén L; Nilsson G; Ohrvik J
Article: PRIMARY CARE DIABETES. 2012;6(2):103-107

Measuring risk online--feasibility of using FINDRISC in an online workplace survey.

Gyberg V; Hasson D; Tuomilehto J; Rydén L
Article: JOURNAL OF INTERVENTIONAL CARDIOLOGY. 2012;25(2):103-110

Effects of myocardial postconditioning on the recruitment of endothelial progenitor cells.

Jung C; Sörensson P; Saleh N; Arheden H; Rydén L; Pernow J
Article: ATHEROSCLEROSIS. 2012;221(1):226-231

Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction.

Jung C; Sörensson P; Saleh N; Arheden H; Rydén L; Pernow J
Article: KARDIOLOGIA POLSKA. 2012;70:S1-S99

European guidelines for cardiac and vascular disease prevention in clinical practice for 2012

Perk J; De Backer G; Gohlke H; Graham I; Reiner Z; Verschuren M; Albus C; Benlian P; Boysen G; Cifkova R; Deaton C; Ebrahim S; Fisher M; Germano G; Hobbs R; Hoes A; Karadeniz S; Mezzani A; Prescott E; Ryden L; Scherer M; Syvanne M; Reimer WJMSO; Vrints C; Wood D; Zamorano JL; Zannad F
Article: CIRCULATION. 2011;124(16):1727-1736

Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).

Mancia G; Schumacher H; Redon J; Verdecchia P; Schmieder R; Jennings G; Yusoff K; Ryden L; Liu GL; Teo K; Sleight P; Yusuf S
Article: JOURNAL OF CARDIOVASCULAR RISK. 2011;18(5):745-753

Policymakers' perceptions of cardiovascular health in Europe.

Gyberg V; Rydén L
Article: DIABETES CARE. 2011;34(9):1902-1907

Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study.

Barzilay JI; Gao P; Rydén L; Schumacher H; Probstfield J; Commerford P; Dans A; Ferreira R; Keltai M; Paolasso E; Yusuf S; Teo K; TRANSCEND Investigators
Article: DIABETOLOGIA. 2011;54(6):1308-1317

Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.

Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L; DIGAMI 2 Investigators
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2011;8(2):143-149

The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes.

Hage C; Grip L; Malmberg K; Rydén L; Wallander M; Saleh N
Article: EUROPEAN HEART JOURNAL. 2010;31(24):3040-3045

Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart survey on diabetes and the heart.

Anselmino M; Ohrvik J; Rydén L; Euro Heart Survey Investigators
Article: DIABETES CARE. 2010;33(11):2451-2456

Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

Mellbin LG; Hamsten A; Malmberg K; Steffensen R; Rydén L; Ohrvik J; Hansen TK
Article: HEART. 2010;96(21):1710-1715

Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction.

Sörensson P; Saleh N; Bouvier F; Böhm F; Settergren M; Caidahl K; Tornvall P; Arheden H; Rydén L; Pernow J
Article: JOURNAL OF INTERNAL MEDICINE. 2010;268(1):75-82

Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes.

Venskutonyte L; Malmberg K; Norhammar A; Wedel H; Rydén L
Article: DIABETES CARE. 2010;33(7):1604-1606

Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial.

Mellbin LG; Rydén L; Brismar K; Morgenthaler NG; Ohrvik J; Catrina SB
Article: JOURNAL OF ELECTROCARDIOLOGY. 2010;43(4):310-317

Prediction of cardiovascular death and myocardial infarction by the QRS-T angle and T vector loop morphology after angioplasty in stable angina pectoris: an 8-year follow-up.

Rubulis A; Bergfeldt L; Rydén L; Jensen J
Article: JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE. 2010;12(1):25

Assessment of myocardium at risk with contrast enhanced steady-state free precession cine cardiovascular magnetic resonance compared to single-photon emission computed tomography.

Sörensson P; Heiberg E; Saleh N; Bouvier F; Caidahl K; Tornvall P; Rydén L; Pernow J; Arheden H
Article: DIABETES TECHNOLOGY & THERAPEUTICS. 2010;12(4):291-295

Glucose monitoring by means of an intravenous microdialysis catheter technique.

Hage C; Mellbin L; Rydén L; Wernerman J
Article: REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. 2010;11(1):87-94

Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting.

Anselmino M; Malmberg K; Mellbin L; Rydén L
Article: JOURNAL OF INTERNAL MEDICINE. 2009;266(5):492-498

Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease.

Settergren M; Böhm F; Rydén L; Pernow J; Kalani M
Article: JOURNAL OF CARDIOVASCULAR RISK. 2009;16 Suppl 2:S58-S60

The political power of heart doctors: with the European Heart Health Charter towards a European policy on cardiovascular disease.

O'Kelly S; Rydén L
Article: ANNALS OF INTERNAL MEDICINE. 2009;151(1):1-W2

Effect of telmisartan on renal outcomes: a randomized trial.

Mann JFE; Schmieder RE; Dyal L; McQueen MJ; Schumacher H; Pogue J; Wang X; Probstfield JL; Avezum A; Cardona-Munoz E; Dagenais GR; Diaz R; Fodor G; Maillon JM; Rydén L; Yu CM; Teo KK; Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study
Article: HEART. 2009;95(9):721-727

Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial.

Mellbin LG; Malmberg K; Waldenström A; Wedel H; Rydén L; DIGAMI 2 investigators
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2009;6(2):71-79

Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study.

Hage C; Norhammar A; Grip L; Malmberg K; Sarkar N; Svane B; Rydén L
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2009;6(2):62-70

A gluco-metabolic risk index with cardiovascular risk stratification potential in patients with coronary artery disease.

Anselmino M; Malmberg K; Rydén L; Ohrvik J
Article: DIABETES OBESITY & METABOLISM. 2009;11(4):323-329

Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study.

Aas A-M; Ohrvik J; Malmberg K; Rydén L; Birkeland KI; DIGAMI 2 Investigators
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2009;11(1):39-47

A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study.

Jarnert C; Landstedt-Hallin L; Malmberg K; Melcher A; Ohrvik J; Persson H; Rydén L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2008;10(11):1080-1087

Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes.

Jarnert C; Melcher A; Caidahl K; Persson H; Rydén L; Eriksson MJ
Article: EUROPEAN HEART JOURNAL. 2008;29(14):1753-1760

Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.

Settergren M; Böhm F; Rydén L; Pernow J
Article: JOURNAL OF CARDIOVASCULAR RISK. 2008;15(2):216-223

Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.

Anselmino M; Malmberg K; Ohrvik J; Rydén L; Euro Heart Survey Investigators
Article: HERZ. 2008;33(3):170-177

Cardiovascular prevention in patients with diabetes and prediabetes.

Anselmino M; Gohlke H; Mellbin L; Rydén L
Article: EUROPEAN HEART JOURNAL. 2008;29(2):166-176

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L; DIGAMI 2 Investigators
Article: EUROPEAN HEART JOURNAL. 2008;29(2):177-184

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.

Anselmino M; Ohrvik J; Malmberg K; Standl E; Rydén L; Euro Heart Survey Investigators
Article: DIABETES CARE. 2008;31(1):36-38

Oral glucose tolerance test: a reliable tool for early detection of glucose abnormalities in patients with acute myocardial infarction in clinical practice: a report on repeated oral glucose tolerance tests from the GAMI study.

Wallander M; Malmberg K; Norhammar A; Rydén L; Tenerz A
Article: REVIEWS IN CARDIOVASCULAR MEDICINE. 2008;9(1):29-38

Early detection and integrated management of dysglycemia in cardiovascular disease: a key factor for decreasing the likelihood of future events.

Anselmino M; Mellbin L; Wallander M; Rydén L
Article: HEART. 2007;93(12):1577-1583

Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission.

Norhammar A; Lindbäck J; Rydén L; Wallentin L; Stenestrand U; Register of Information and Knowledge about Swedis
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2007;9(10):1051-1057

Increasing glucose levels and BMI predict future heart failure experience from the Reykjavík Study.

Thrainsdottir IS; Aspelund T; Gudnason V; Malmberg K; Sigurdsson G; Thorgeirsson G; Hardarson T; Rydén L
Article: DIABETES CARE. 2007;30(9):2343-2348

IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes.

Wallander M; Norhammar A; Malmberg K; Ohrvik J; Rydén L; Brismar K
Article: JOURNAL OF CARDIOVASCULAR RISK. 2007;14(3):366-372

Predictors of healthy behaviours in Swedish school children.

Villard LC; Rydén L; Ståhle A
Journal article: JOURNAL OF HYPERTENSION. 2007;25(6):1462-1536

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Mancia G; De Backer G; Dominiczak A; Cifkova R; Fagard R; Germano G; Grassi G; Heagerty AM; Kjeldsen SE; Laurent S; Narkiewicz K; Ruilope L; Rynkiewicz A; Schmieder RE; Boudier HAJS; Zanchetti A; Vahanian A; Camm J; De Caterina R; Dean V; Dickstein K; Filippatos G; Funck-Brentano C; Hellemans I; Kristensen SD; McGregor K; Sechtem U; Silber S; Tendera M; Widimsky P; Zamorano JL; Erdine S; Kiowski W; Agabiti-Rosei E; Ambrosioni E; Lindholm LH; Viigimaa M; Adamopoulos S; Agabiti-Rosei E; Ambrosioni E; Bertomeu V; Clement D; Erdine S; Farsang C; Gaita D; Lip G; Mallion J-M; Manolis AJ; Nilsson PM; O'Brien E; Ponikowski P; Redon J; Ruschitzka F; Tamargo J; van Zwieten P; Waeber B; Williams B; Management of Arterial Hypertension of the Europea; European Society of Cardiology
Journal article: EUROPEAN HEART JOURNAL. 2007;28(12):1105-1187

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Mancia G; De Backer G; Dominiczak A; Cifkova R; Fagard R; Germano G; Grassi G; Heagerty AM; Kjeldsen SE; Laurent S; Narkiewicz K; Ruilope L; Rynkiewicz A; Schmieder RE; Struijker Boudier HAJ; Zanchetti A; Vahanian A; Camm J; De Caterina R; Dean V; Dickstein K; Filippatos G; Funck-Brentano C; Hellemans I; Kristensen SD; McGregor K; Sechtem U; Silber S; Tendera M; Widimsky P; Zamorano JL; Kjeldsen SE; Erdine S; Narkiewicz K; Kiowski W; Agabiti-Rosei E; Ambrosioni E; Cifkova R; Dominiczak A; Fagard R; Heagerty AM; Laurent S; Lindholm LH; Mancia G; Manolis A; Nilsson PM; Redon J; Schmieder RE; Struijker-Boudier HAJ; Viigimaa M; Filippatos G; Adamopoulos S; Agabiti-Rosei E; Ambrosioni E; Bertomeu V; Clement D; Erdine S; Farsang C; Gaita D; Kiowski W; Lip G; Mallion J-M; Manolis AJ; Nilsson PM; O'Brien E; Ponikowski P; Redon J; Ruschitzka F; Tamargo J; van Zwieten P; Viigimaa M; Waeber B; Williams B; Zamorano JL; The task force for the management of arterial hype; The task force for the management of arterial hype
Article: JOURNAL OF CARDIOVASCULAR RISK. 2007;14(2):326-332

Impact of time trends and increasing age on health behaviour of Swedish school children.

Villard LC; Rydén L; Ohrvik J; Ståhle A
Article: JOURNAL OF CARDIOVASCULAR RISK. 2007;14(1):28-36

Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart.

Anselmino M; Bartnik M; Malmberg K; Rydén L; Euro Heart Survey Investigators
Article: EUROPEAN HEART JOURNAL. 2007;28(3):310-315

Sex-related aspects on abnormal glucose regulation in patients with coronary artery disease.

Dotevall A; Rosengren A; Bartnik M; Malmberg K; Ohrvik J; Simoons M; Rydén L; European Heart Survey Investigators
Article: HEART. 2007;93(1):72-77

Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart.

Bartnik M; Rydén L; Malmberg K; Ohrvik J; Pyörälä K; Standl E; Ferrari R; Simoons M; Soler-Soler J; Euro Heart Survey Investigators
Article: EUROPEAN HEART JOURNAL. 2006;27(24):2969-2974

Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.

Lenzen M; Ryden L; Ohrvik J; Bartnik M; Malmberg K; Scholte Op Reimer W; Simoons ML; Euro Heart Survey Investigators
Article: DIABETOLOGIA. 2006;49(10):2247-2255

Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction.

Wallander M; Brismar K; Ohrvik J; Rydén L; Norhammar A
Article: JOURNAL OF CARDIOVASCULAR RISK. 2006;13(1):91-97

Long-term influence of a health education programme on knowledge and health behaviour in children.

Lindberg LC; Ståhle A; Rydén L
Article: DIABETOLOGIA. 2005;48(11):2229-2235

Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study.

Wallander M; Bartnik M; Efendic S; Hamsten A; Malmberg K; Ohrvik J; Rydén L; Silveira A; Norhammar A
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(5):465-471

Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavík Study.

Thrainsdottir IS; Aspelund T; Hardarson T; Malmberg K; Sigurdsson G; Thorgeirsson G; Gudnason V; Rydén L
Article: EUROPEAN HEART JOURNAL. 2005;26(7):650-661

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.

Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt P; MacLeod K; Laakso M; Torp-Pedersen C; Waldenström A; DIGAMI 2 Investigators
Article: DIABETES CARE. 2005;28(3):612-616

The association between glucose abnormalities and heart failure in the population-based Reykjavik study.

Thrainsdottir IS; Aspelund T; Thorgeirsson G; Gudnason V; Hardarson T; Malmberg K; Sigurdsson G; Rydén L
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2005;2(1):24-30

Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus.

Von Bibra H; Thrainsdottir IS; Hansen A; Dounis V; Malmberg K; Rydén L
Article: HEALTH PSYCHOLOGY. 2005;24(1):41-48

Long-term effects of lifestyle behavior change in coronary artery disease: effects on recurrent coronary events after percutaneous coronary intervention.

Lisspers J; Sundin O; Ohman A; Hofman-Bang C; Rydén L; Nygren A
Article: EUROPEAN HEART JOURNAL. 2004;25(22):1990-1997

Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.

Bartnik M; Malmberg K; Norhammar A; Tenerz A; Ohrvik J; Rydén L
Article: EUROPEAN HEART JOURNAL. 2004;25(21):1880-1890

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.

Bartnik M; Rydén L; Ferrari R; Malmberg K; Pyörälä K; Simoons M; Standl E; Soler-Soler J; Ohrvik J; Euro Heart Survey Investigators
Article: JOURNAL OF INTERNAL MEDICINE. 2004;256(4):288-297

Abnormal glucose tolerance--a common risk factor in patients with acute myocardial infarction in comparison with population-based controls.

Bartnik M; Malmberg K; Hamsten A; Efendic S; Norhammar A; Silveira A; Tenerz A; Ohrvik J; Rydén L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2004;6(5):627-634

Six years follow-up of an implanted SvO(2) sensor in the right ventricle.

Kjellström B; Linde C; Bennett T; Ohlsson A; Ryden L
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2004;44(1):101-108

Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure.

Thrainsdottir IS; von Bibra H; Malmberg K; Rydén L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2004;6(4):467-475

Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).

Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ; CARMEN investigators and co-ordinators
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2004;1(1):40-43

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.

Thrainsdottir I; Malmberg K; Olsson A; Gutniak M; Rydén L
Article: EUROPEAN HEART JOURNAL. 2004;25(7):611-616

Patient access to medical technology across Europe.

Rydén L; Stokoe G; Breithardt G; Lindemans F; Potgieter A; Task Force 2 of the Cardiovascular Round Table of
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2004;43(4):585-591

Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.

Norhammar A; Malmberg K; Diderholm E; Lagerqvist B; Lindahl B; Rydén L; Wallentin L
Article: CARDIOVASCULAR DRUGS AND THERAPY. 2004;18(1):57-66

The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).

Remme WJ; Riegger G; Hildebrandt P; Komajda M; Jaarsma W; Bobbio M; Soler-Soler J; Scherhag A; Lutiger B; Rydén L
Article: DIABETES CARE. 2003;26(10):2770-2776

Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes.

Tenerz A; Norhammar A; Silveira A; Hamsten A; Nilsson G; Rydén L; Malmberg K
Article: AMERICAN JOURNAL OF CARDIOLOGY. 2003;92(1):95-99

Effects of biventricular pacing on myocardial blood flow and oxygen consumption using carbon-11 acetate positron emission tomography in patients with heart failure.

Braunschweig F; Sörensen J; von Bibra H; Olsson A; Rydén L; Långström B; Linde C
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2003;5(3):253-259

Central hemodynamic responses during serial exercise tests in heart failure patients using implantable hemodynamic monitors.

Ohlsson A; Steinhaus D; Kjellström B; Ryden L; Bennett T
Article: EUROPEAN HEART JOURNAL. 2003;24(9):838-844

Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction.

Norhammar A; Malmberg K; Rydén L; Tornvall P; Stenestrand U; Wallentin L; Register of Information and Knowledge about Swedis
Article: PEPTIDES. 2003;24(4):569-578

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.

Kavianipour M; Ehlers MR; Malmberg K; Ronquist G; Ryden L; Wikström G; Gutniak M
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2003;41(4):565-571

Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system.

Adamson PB; Magalski A; Braunschweig F; Böhm M; Reynolds D; Steinhaus D; Luby A; Linde C; Ryden L; Cremers B; Takle T; Bennett T
Article: INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE. 2003;10(3):191-204

Comparing multifactorial lifestyle interventions and stress management in coronary risk reduction.

Sundin O; Lisspers J; Hofman-Bang C; Nygren A; Rydén L; Ohman A
Article: HEART. 2003;89(1):42-48

Mode of death in heart failure: findings from the ATLAS trial.

Poole-Wilson PA; Uretsky BF; Thygesen K; Cleland JGF; Massie BM; Rydén L; Atlas Study Group. Assessment of treatment with li
Article: PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY. 2003;26(1 Pt 1):114-124

Lessons from the first patient with an implanted pacemaker: 1958-2001.

Larsson B; Elmqvist H; Rydén L; Schüller H
Article: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2003;5(B):B33-B41

Managing heart disease -: Diabetes and the heart:: compromised myocardial function -: a common challenge

Bartnik M; Malmberg K; Rydén L
Article: JOURNAL OF INTERNAL MEDICINE. 2002;252(6):561-569

Significant predictors of poor prognosis in women aged

Al-Khalili F; Svane B; Janszky I; Rydén L; Orth-Gomér K; Schenck-Gustafsson K

Article: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2002;4(G):G21-G25

Who are the enemies?: Diabetes mellitus -: a major risk factor for ischaemic myocardial injury:: new directions in the management of acute coronary syndromes in the diabetic patient

Rydèn L; Malmberg K
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2002;40(3):339-345

Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II.

Segawa D; Sjöquist P-O; Wang Q-D; Gonon A; Rydén L
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2002;40(2):228-234

Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I.

Wang Q-D; Segawa D; Ericsson H; Sjöquist P-O; Johansson L; Rydén L
Article: LANCET. 2002;359(9324):2140-2144

Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.

Norhammar A; Tenerz A; Nilsson G; Hamsten A; Efendíc S; Rydén L; Malmberg K
Article: EUROPEAN HEART JOURNAL. 2002;23(1):59-69

Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure.

Braunschweig F; Linde C; Eriksson MJ; Hofman-Bang C; Rydén L
Article: EUROPEAN HEART JOURNAL. 2001;22(20):1954-1959

Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications.

Frykman V; Beerman B; Rydén L; Rosenqvist M; Medical Products Agency; Swedish Society of Cardiology
Article: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2001;3(L):L21-L25

Pharmacological therapy for hypertrophic cardiomyopathy:: what is the evidence for success?

Rydén L; Gadler F
Article: EUROPEAN HEART JOURNAL. 2001;22(17):1601-1612

Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.

Cleland JG; Thygesen K; Uretsky BF; Armstrong P; Horowitz JD; Massie B; Packer M; Poole-Wilson PA; Rydén L; ATLAS investigators
Article: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2001;3(C):C28-C35

Pharmacological tools for the limitation of myocardial reperfusion injury -: Experimental evidence

Rydén L; Sjöquist PO; Wang WD
Article: EUROPEAN HEART JOURNAL. 2001;22(11):942-954

Continuous ambulatory monitoring of absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure using an implantable haemodynamic monitor: results of a 1 year multicentre feasibility study.

Ohlsson A; Kubo SH; Steinhaus D; Connelly DT; Adler S; Bitkover C; Nordlander R; Rydén L; Bennett T
Article: ARCHIVES OF INTERNAL MEDICINE (CHICAGO, ILL. : 1908). 2001;161(2):165-171

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.

Massie BM; Armstrong PW; Cleland JG; Horowitz JD; Packer M; Poole-Wilson PA; Rydén L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2000;2(4):447-454

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.

Sculpher MJ; Poole L; Cleland J; Drummond M; Armstrong PW; Horowitz JD; Massie BM; Poole-Wilson PA; Ryden L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2000;2(4):399-406

Reduction of hospital days by biventricular pacing.

Braunschweig F; Linde C; Gadler F; Rydén L
Article: CORONARY ARTERY DISEASE. 2000;11(8):579-584

Intracoronary ultrasound measurements in women with myocardial infarction without significant coronary lesions.

al-Khalili F; Svane B; Di Mario C; Prati F; Mallus MT; Rydén L; Schenck-Gustafsson K
Article: EUROPEAN HEART JOURNAL. 2000;21(23):1967-1978

Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.

Rydén L; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Packer M; Poole-Wilson PA
Article: LAKARTIDNINGEN. 2000;97(46):5372-5374

[Sudden death in an adult professional with no visible sickness--some reflections].

Rydén L; Bergfeldt L
Article: LAKARTIDNINGEN. 2000;97(40):4450-4458

[Biventricular pacing as a new therapeutic method in heart failure. An alternative for patients with intraventricular conduction disorders].

Braunschweig F; Gadler F; Linde C; Kjellström B; Rydén L
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2000;36(3):338-343

Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashort-acting calcium antagonist clevidipine.

Segawa D; Sjöquist PO; Wang QD; Gonon A; Nordlander M; Rydén L
Article: HEART. 2000;84 Suppl 1(Suppl 1):i23-5:discussion i50-I25

Managing cardiovascular risk in patients with diabetes.

Rydén L
Article: LANCET. 2000;356(9230):671-672

European cardiology: 50 years.

Verheugt FW; Martin JF; Ryden L
Article: CIRCULATION. 2000;102(6):611-616

Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial.

Uretsky BF; Thygesen K; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Packer M; Poole-Wilson PA; Ryden L
Article: AMERICAN HEART JOURNAL. 2000;139(6):971-978

Clinical importance of risk factors and exercise testing for prediction of significant coronary artery stenosis in women recovering from unstable coronary artery disease: the Stockholm Female Coronary Risk Study.

Al-Khalili F; Svane B; Wamala SP; Orth-Gomér K; Rydén L; Schenck-Gustafsson K
Article: EUROPEAN HEART JOURNAL. 2000;21(9):733-739

Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study.

Almbrand B; Johannesson M; Sjöstrand B; Malmberg K; Rydén L
Article: THROMBOSIS RESEARCH. 2000;98(1):39-49

Haemostatic function in patients undergoing coronary artery bypass grafting: peroperative perturbations and relations to saphenous vein graft closure.

Moor E; Blombäck M; Silveira A; Wiman B; Cederlund K; Bergstrand L; Ivert T; Rydén L; Hamsten A
Article: CIRCULATION. 1999;100(23):2312-2318

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Packer M; Poole-Wilson PA; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Rydén L; Thygesen K; Uretsky BF
Article: DIABETES CARE. 1999;22(11):1827-1831

Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients.

Norhammar AM; Rydén L; Malmberg K
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 1999;34(4):512-517

Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.

Shimizu M; Wang QD; Sjöquist PO; Rydén L
Article: EUROPEAN HEART JOURNAL. 1999;20(20):1475-1484

Improved physical fitness and quality of life following training of elderly patients after acute coronary events. A 1 year follow-up randomized controlled study.

Ståhle A; Mattsson E; Rydén L; Unden A; Nordlander R
Article: EUROPEAN HEART JOURNAL. 1999;20(20):1465-1474

Two-year results of a controlled study of residential rehabilitation for patients treated with percutaneous transluminal coronary angioplasty. A randomized study of a multifactorial programme.

Hofman-Bang C; Lisspers J; Nordlander R; Nygren A; Sundin O; Ohman A; Rydén L
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 1999;380(2-3):123-128

Cardiac inotropic vs. chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine.

Segawa D; Sjöquist PO; Nordlander M; Wang QD; Gonon A; Rydén L
Article: CARDIOVASCULAR DRUGS AND THERAPY. 1999;13(4):347-353

The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion.

Shimizu M; Wang QD; Sjöquist PO; Rydén L
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 1999;34(1):78-81

The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts.

Shimizu M; Wang QD; Sjöquist PO; Rydén L
Article: EUROPEAN HEART JOURNAL. 1999;20(11):789-795

Diabetes mellitus and congestive heart failure. Further knowledge needed.

Soläng L; Malmberg K; Rydén L
Article: CIRCULATION. 1999;99(20):2626-2632

Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.

Malmberg K; Norhammar A; Wedel H; Rydén L
Article: JOURNAL OF REHABILITATION MEDICINE. 1999;31(2):101-107

Effects of organized aerobic group training in elderly patients discharged after an acute coronary syndrome. A randomized controlled study.

Ståhle A; Nordlander R; Rydén L; Mattsson E
Article: AMERICAN JOURNAL OF CARDIOLOGY. 1999;83(6):903-907

Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy.

Linde C; Gadler F; Kappenberger L; Rydén L
Article: AMERICAN JOURNAL OF CARDIOLOGY. 1999;83(4):553-557

Rapid return of left ventricular outflow tract obstruction and symptoms following cessation of long-term atrioventricular synchronous pacing for obstructive hypertrophic cardiomyopathy.

Gadler F; Linde C; Rydén L
Article: JOURNAL OF PSYCHOSOMATIC RESEARCH. 1999;46(2):143-154

Behavioral effects of a comprehensive, multifactorial program for lifestyle change after percutaneous transluminal coronary angioplasty: a prospective, randomized controlled study.

Lisspers J; Sundin O; Hofman-Bang C; Nordlander R; Nygren A; Rydén L; Ohman A
Article: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 1999;33(1):9-16

Multifactorial evaluation of a program for lifestyle behavior change in rehabilitation and secondary prevention of coronary artery disease.

Lisspers J; Hofman-Bang C; Nordlander R; Rydèn L; Sundin O; Ohman A; Nygren A
Article: EUROPEAN HEART JOURNAL. 1998;19(11):1648-1656

Social relations and extent and severity of coronary artery disease. The Stockholm Female Coronary Risk Study.

Orth-Gomér K; Horsten M; Wamala SP; Mittleman MA; Kirkeeide R; Svane B; Rydén L; Schenck-Gustafsson K
Article: EUROPEAN HEART JOURNAL. 1998;19(11):1628-1631

Re-use of devices in cardiology. Proceedings from a Policy Conference at the European Heart House, 5-6 February, 1998.

Rydén L
Article: THROMBOSIS AND HAEMOSTASIS. 1998;80(2):220-224

Coagulation factor V (Arg506-->Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting.

Moor E; Silveira A; van't Hooft F; Tornvall P; Blombäck M; Wiman B; Rydén L; Hamsten A
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 1998;32(2):231-238

Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury.

Shimizu M; Wang QD; Sjöquist PO; Rydén L
Article: LAKARTIDNINGEN. 1998;95(24):2780-2781

[Better and cheaper care in heart failure. Efficient care programs save resources].

Rydén L
Article: FREE RADICAL BIOLOGY AND MEDICINE. 1998;24(5):726-731

The lipid peroxidation inhibitor indenoindole H290/51 protects myocardium at risk of injury induced by ischemia-reperfusion.

Shimizu M; Wang QD; Sjöquist PO; Rydén L
Article: JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS. 1998;39(2):81-89

Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.

Uriuda Y; Wang QD; Hatori N; Nordlander R; Sjöquist PO; Mattsson C; Rydén L
Article: CARDIOVASCULAR DRUGS AND THERAPY. 1998;12(1):37-45

Myocardioprotective effects of felodipine in an antihypertensive dosage: an experimental study in pigs.

Shimizu M; Wang QD; Sjöquist PO; Nordlander R; Rydén L
Article: EUROPEAN HEART JOURNAL. 1998;19(1):174-184

Continuous ambulatory haemodynamic monitoring with an implantable system. The feasibility of a new technique.

Ohlsson A; Nordlander R; Bennett T; Bitkover C; Kjellström B; Lee B; Rydén L
Article: EUROPEAN HEART JOURNAL. 1998;19(1):154-157

Re-used pacemakers--as safe as new? A retrospective case-control study.

Linde CL; Bocray A; Jonsson H; Rosenqvist M; Rådegran K; Rydén L
Article: EUROPEAN HEART JOURNAL. 1997;18(9):1416-1425

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
Article: CORONARY ARTERY DISEASE. 1997;8(6):327-334

Markers of risk after acute myocardial infarction. A comparison of clinical variables, ambulatory and exercise electrocardiography, echocardiography, and stress echocardiography.

Quintana M; Lindvall K; Brolund F; Storck N; Lindblad LE; Rydén L
Article: EUROPEAN HEART JOURNAL. 1997;18(4):636-642

Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest.

Gadler F; Linde C; Juhlin-Dannfelt A; Ribeiro A; Rydén L
Article: CARDIOVASCULAR RESEARCH. 1997;34(1):248-253

Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study.

Malmberg K; Rydén L; Hamsten A; Herlitz J; Waldenström A; Wedel H
Article: CIRCULATION. 1997;95(2):329-334

Lipoprotein(a) as a determinant of coronary heart disease in young women.

Orth-Gomér K; Mittleman MA; Schenck-Gustafsson K; Wamala SP; Eriksson M; Belkic K; Kirkeeide R; Svane B; Rydén L
Article: EUROPEAN HEART JOURNAL. 1996;17(12):1902-1910

Long-term recording of cardiac output via an implantable haemodynamic monitoring device.

Ohlsson A; Bennett T; Ottenhoff F; Bitkover C; Kjellström B; Nordlander R; Aström H; Rydén L
Article: LAKARTIDNINGEN. 1996;93(41):3566-3572

[Pacemaker in hypertrophic obstructive cardiomyopathy. A new efficient treatment of heart disease].

Gadler F; Juhlin-Dannfelt A; Linde C; Ribeiro A; Rydén L
Article: PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY. 1996;19(9):1279-1286

The effect of ventricular activation sequence on cardiac performance during pacing.

Rosenqvist M; Bergfeldt L; Haga Y; Rydén J; Rydén L; Owall A
Article: EUROPEAN HEART JOURNAL. 1996;17(9):1337-1344

Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction.

Malmberg K; Rydén L; Hamsten A; Herlitz J; Waldenström A; Wedel H
Article: CARDIOVASCULAR RESEARCH. 1996;32(2):320-327

Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.

Uriuda Y; Wang QD; Grip L; Rydén L; Sjöquist PO; Mattsson C
Article: JOURNAL OF INTERVENTIONAL CARDIOLOGY. 1996;9(4):307-309

Hypertrophic obstructive cardiomyopathy

Ryden L
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 1996;28(1):134-141

Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occlusion/reperfusion porcine heart model.

Tadokoro H; Miyazaki A; Satomura K; Rydén L; Kaul S; Kar S; Corday E; Drury K
Article: SAMJ SOUTH AFRICAN MEDICAL JOURNAL. 1996;86 Suppl 3:C152-C158

Cardioversion of atrial fibrillation. State of the art, 1995.

Rydén L; Malmberg K
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 1996;27(5):1219-1224

Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy.

Gadler F; Linde C; Juhlin-Dannfeldt A; Ribeiro A; Rydén L
Article: CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS. 1996;2(2):107-115

Coronary angioplasty in patients with unstable angina, with special reference to preceding treatment with antithrombin III and heparin

Grip L; Hellekant C; Herzfeld I; Malmberg K; Svane B; Szamosi A; Velander M; Ryden L
Article: CARDIOVASCULAR RESEARCH. 1996;31(1):82-92

Coronary venous drug infusion in the ischaemic-reperfused isolated rat heart.

Uriuda Y; Wang QD; Li XS; Sjoquist PO; Nordlander R; Ryden L
Article: TRACE ELEMENTS IN MEDICINE. 1996;13(2):69-74

Impaired myocardial function following chronic cobalt exposure in an isolated rat heart model

Haga Y; Clyne N; Hatori N; HoffmanBang C; Pehrsson SK; Ryden L
Article: AMERICAN JOURNAL OF CARDIOLOGY. 1995;76(16):1115-1121

Prognostic value of predischarge exercise stress echocardiography after acute myocardial infarction.

Quintana M; Lindvall K; Rydén L; Brolund F
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 1995;26(6):1501-1507

Dynamic on-line vectorcardiography improves and simplifies in-hospital ischemia monitoring of patients with unstable angina.

Dellborg M; Malmberg K; Rydén L; Svensson AM; Swedberg K
Article: CORONARY ARTERY DISEASE. 1995;6(11):865-873

Prognostic value of exercise stress testing versus ambulatory electrocardiography after acute myocardial infarction: a 3 year follow-up study.

Quintana M; Lindvall K; Brolund F; Eriksson SV; Rydén L
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 1995;26(5):770-776

Myocardial release of endothelin (ET) and enhanced ET(A) receptor-mediated coronary vasoconstriction after coronary thrombosis and thrombolysis in pigs.

Wang QD; Uriuda Y; Pernow J; Hemsén A; Sjöquist PO; Rydén L
Article: EUROPEAN HEART JOURNAL. 1995;16(9):1215-1222

Monitoring of mixed venous oxygen saturation and pressure from biosensors in the right ventricle. A 24 hour study in patients with heart failure.

Ohlsson A; Beck R; Bennett T; Nordlander R; Rydén J; Aström H; Rydén L
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 1995;26(1):57-65

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year.

Malmberg K; Rydén L; Efendic S; Herlitz J; Nicol P; Waldenström A; Wedel H; Welin L
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 1995;25(6):924-929

Beneficial effects of H290/51, a new lipid peroxidation inhibitor, on functional recovery after ischemia and reperfusion in isolated cold-arrested rat hearts.

Wang QD; Uriuda Y; Li XS; Nordlander R; Sjöquist PO; Rydén L
Article: AMERICAN JOURNAL OF CARDIOLOGY. 1995;75(14):919-923

Results of atrioventricular synchronous pacing with optimized delay in patients with severe congestive heart failure.

Linde C; Gadler F; Edner M; Nordlander R; Rosenqvist M; Rydén L
Article: JOURNAL OF CARDIAC FAILURE. 1995;1(2):161-168

Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer.

Ohlsson A; Bennett T; Nordlander R; Rydén J; Aström H; Rydén L
Article: LAKARTIDNINGEN. 1995;92(7):622-627

[Thrombolysis is replaced by angioplasty. A change of strategy in the Swedish care of myocardial infarction?].

Herzfeld I; Grip L; Velander M; Rydén L
Article: ACTA PHYSIOLOGICA. 1995;153(1):13-20

Influence of coronary venous retroinfusion and vasodilatation on regional myocardial blood flow measurement with microspheres. An analysis of 'microsphere loss' from ischaemic and reperfused porcine hearts.

Haga Y; Nordlander R; Sjöquist PO; Rydén L
Visa fler

Alla övriga publikationer

Letter: CARDIOVASCULAR DIABETOLOGY. 2024;23(1):104

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.

Schnell O; Barnard-Kelly K; Battelino T; Ceriello A; Larsson HE; Fernández-Fernández B; Forst T; Frias J-P; Gavin JR; Giorgino F; Groop P-H; Heerspink HJL; Herzig S; Hummel M; Huntley G; Ibrahim M; Itzhak B; Jacob S; Ji L; Kosiborod M; Lalic N; Macieira S; Malik RA; Mankovsky B; Marx N; Mathieu C; Müller TD; Ray K; Rodbard HW; Rossing P; Rydén L; Schumm-Draeger P-M; Schwarz P; Škrha J; Snoek F; Tacke F; Taylor B; Jeppesen BT; Tesfaye S; Topsever P; Vilsbøll T; Yu X; Standl E
Letter: JOURNAL OF INTERNAL MEDICINE. 2023;294(6):819

The 1923 Nobel Prize for the discovery of insulin in a 100-year perspective.

Rydén L; Lindsten M
Editorial comment: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):277

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.

Ceriello A; Rodbard HW; Battelino T; Brosius F; Cosentino F; Green J; Ji L; Kellerer M; Koob S; Kosiborod M; Lalic N; Marx N; Nedungadi TP; Parkin CG; Rydén L; Sheu WH-H; Standl E; Vandvik PO; Schnell O; Taskforce of the Guideline Workshop
Editorial comment: EUROPEAN HEART JOURNAL. 2023;44(28):2557-2559

Risk prediction in patients with diabetes: is SCORE 2D the perfect solution?

Rydén L; Ferrannini G; Standl E
Review: DIABETES THERAPY. 2023;14(7):1093-1110

Guardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 Diabetes.

Kanumilli N; Butler J; Makrilakis K; Rydén L; Vallis M; Wanner C; Zieroth S; Alhussein A; Cheng A
Review: BMJ-BRITISH MEDICAL JOURNAL. 2023;381:e074068

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

Shi Q; Nong K; Vandvik PO; Guyatt GH; Schnell O; Rydén L; Marx N; Brosius FC; Mustafa RA; Agarwal A; Zou X; Mao Y; Asadollahifar A; Chowdhury SR; Zhai C; Gupta S; Gao Y; Lima JP; Numata K; Qiao Z; Fan Q; Yang Q; Jin Y; Ge L; Yang Q; Zhu H; Yang F; Chen Z; Lu X; He S; Chen X; Lyu X; An X; Chen Y; Hao Q; Standl E; Siemieniuk R; Agoritsas T; Tian H; Li S
Editorial comment: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):59

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.

Schnell O; Battelino T; Bergenstal R; Birkenfeld AL; Ceriello A; Cheng A; Davies M; Edelman S; Forst T; Giorgino F; Green J; Groop P-H; Hadjadj S; J L Heerspink H; Hompesch M; Izthak B; Ji L; Kanumilli N; Mankovsky B; Mathieu C; Miszon M; Mustafa R; Nauck M; Pecoits-Filho R; Pettus J; Ranta K; Rodbard HW; Rossing P; Ryden L; Schumm-Draeger P-M; Solomon SD; Škrha J; Topsever P; Vilsbøll T; Wilding J; Standl E
Editorial comment: DIABETES CARE. 2022;45(10):e146-e147

Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis.

Ferrannini G; Mellbin LG; Kirabo F; Ramasundarahettige C; Gerstein HC; Rydén L
Editorial comment: NEW ENGLAND JOURNAL OF MEDICINE. 2022;387(12):1136-1138

After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk.

Rydén L; Standl E
Other: EUROPEAN HEART JOURNAL. 2022;43(26):2438-2439

Obituary Joep Perk In memoriam

Ryden L
Editorial comment: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):50

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.

Schnell O; Battelino T; Bergenstal R; Blüher M; Böhm M; Brosius F; Carr RD; Ceriello A; Forst T; Giorgino F; Guerci B; Heerspink HJL; Itzhak B; Ji L; Kosiborod M; Lalić N; Lehrke M; Marx N; Nauck M; Rodbard HW; Rosano GMC; Rossing P; Rydén L; Santilli F; Schumm-Draeger P-M; Vandvik PO; Vilsbøll T; Wanner C; Wysham C; Standl E
Editorial comment: LANCET DIABETES & ENDOCRINOLOGY. 2022;10(1):3-5

Is the impact of add on heart failure therapy influenced by background therapy?

Rydén L; Ferrannini G
Review: CURRENT CARDIOLOGY REPORTS. 2021;23(10):136

INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions : In Partnership with the World Heart Federation, European Society of Cardiology, Asia Pacific Society of Cardiology, InterAmerican Society of Cardiology, and PanAfrican Society of Cardiology.

McEvoy JW; Jennings C; Kotseva K; De Backer G; De Bacquer D; Erlund I; Lip GYH; Ray KK; Rydén L; Adamska A; Wood DA
Review: DIABETES RESEARCH AND CLINICAL PRACTICE. 2021;177:108870

Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020.

Marx N; Ryden L; Brosius F; Ceriello A; Cheung M; Cosentino F; Green J; Kellerer M; Koob S; Kosiborod M; Prashant Nedungadi T; Rodbard HW; Vandvik PO; Ji L; Sheu WH-H; Standl E; Schnell O
Editorial comment: DIABETES RESEARCH AND CLINICAL PRACTICE. 2021;175:108844

Heart failure at the crossroads of cardiology and diabetology.

Standl E; Rydén L
Editorial comment: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2021;28(1):18-21

Is cardioprotection with GLP-1 receptor agonists a class effect?

Rydén L; Ferrannini G; Mellbin L
Editorial comment: DIABETES TECHNOLOGY & THERAPEUTICS. 2020;22(7):546-552

Proceedings of the Guideline Workshop 2019: Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases, and Kidney Diseases.

Marx N; Rydén L; Brosius F; Ceriello A; Cheung M; Cosentino F; Green J; Kellerer M; Koob S; Kosiborod M; Nedungadi P; Rodbard HW; Vandvik PO; Standl E; Schnell O
Editorial comment: DIABETES RESEARCH AND CLINICAL PRACTICE. 2020;162:108092

Proceedings of the Guideline Workshop 2019 - Strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases.

Marx N; Rydén L; Brosius F; Ceriello A; Cheung M; Cosentino F; Green J; Kellerer M; Koob S; Kosiborod M; Nedungadi P; Rodbard HW; Vandvik PO; Standl E; Schnell O
Letter: DIABETES CARE. 2020;43(1):e9

Response to Comment on Norhammar et al. Undetected Dysglycemia Is an Important Risk Factor for Two Common Diseases, Myocardial Infarction and Periodontitis: A Report From the PAROKRANK Study. Diabetes Care 2019;42:1504-1511.

Norhammar A; Kjellström B; Habib N; Gustafsson A; Klinge B; Nygren Å; Näsman P; Svenungsson E; Rydén L
Editorial comment: GLOBAL HEART. 2019;14(3):215-240

A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes.

Mitchell S; Malanda B; Damasceno A; Eckel RH; Gaita D; Kotseva K; Januzzi JL; Mensah G; Plutzky J; Prystupiuk M; Ryden L; Thierer J; Virani SS; Sperling L
Letter: ANNALS OF INTERNAL MEDICINE. 2019;170(4):277-280

Antiphospholipid Antibodies in Patients With Myocardial Infarction.

Grosso G; Sippl N; Kjellström B; Amara K; de Faire U; Elvin K; Lindahl B; Näsman P; Rydén L; Norhammar A; Svenungsson E
Review: CLINICAL SCIENCE. 2018;132(18):2003-2012

Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data.

Ferrannini G; Rydén L
Editorial comment: EUROPEAN HEART JOURNAL. 2018;39(29):2746-2748

On the prognostic value of post-load glucose in patients with coronary artery disease.

Rydén L; Shahim B; Standl E
Letter: CIRCULATION. 2018;137(1):88-90

Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention).

Gerstein HC; Jung H; Rydén L; Diaz R; Gilbert RE; Yusuf S; ORIGIN Investigators
Corrigendum: CARDIOVASCULAR DIABETOLOGY. 2017;16(1):150

Correction to: Updates on cardiovascular outcome trials in diabetes.

Schnell O; Rydén L; Standl E; Ceriello A; D&CVD EASD Study Group
Review: SAMJ SOUTH AFRICAN MEDICAL JOURNAL. 2017;28(5):331-337

Anaemia and iron deficiency in heart failure: epidemiological gaps, diagnostic challenges and therapeutic barriers in sub-Saharan Africa.

Makubi A; Lwakatare J; Ogah OS; Rydén L; Lund LH; Makani J
Review: CARDIOVASCULAR DIABETOLOGY. 2017;16(1):128

Updates on cardiovascular outcome trials in diabetes.

Schnell O; Rydén L; Standl E; Ceriello A; D&CVD EASD Study Group
Editorial comment: CIRCULATION. 2017;135(20):1894-1896

New Hope For People With Dysglycemia and Cardiovascular Disease Manifestations: Reduction of Acute Coronary Events With Pioglitazone.

Rydén L; Mellbin L
Letter: LANCET DIABETES & ENDOCRINOLOGY. 2017;5(5):325-326

Corrections needed to 2016 ESC and AHA guidelines on heart failure.

Rydén L; Van de Werf F; Armstrong PW; McGuire DK; Standl E; Peterson ED; Holman RR
Review: LANCET DIABETES & ENDOCRINOLOGY. 2017;5(5):391-402

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.

Standl E; Schnell O; McGuire DK; Ceriello A; Rydén L
Letter: LANCET DIABETES & ENDOCRINOLOGY. 2016;4(9):732-733

Oral glucose tolerance testing and cardiovascular disease.

Rydén L; Gyberg V; Schnell O; Tuomilehto J; EUROASPIRE IV investigators
Letter: CIRCULATION. 2016;134(1):e2

Response by Rydén to Letter Regarding Article, "Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study".

Rydén L
Editorial comment: CLINICAL THERAPEUTICS. 2016;38(6):1279-1287

Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.

Rydén L; Shahim B; Mellbin L
Editorial comment: EUROPEAN HEART JOURNAL. 2016;37(19):1535-1537

Treatment of diabetes and heart failure: joint forces.

Swedberg K; Rydén L
Editorial comment: CARDIOLOGY. 2016;134(4):411-412

Problems, Pitfalls and Encouraging Information on Patients with Diabetes and Heart Failure.

Norhammar A; Johansson I; Rydén L
Editorial comment: EUROPEAN HEART JOURNAL. 2015;36(16):950-951

EURObservational research programme: EUROASPIRE.

Kotseva K; Rydén L; De Backer G; De Bacquer D; Wood D
Review: DIABETES & VASCULAR DISEASE RESEARCH. 2014;11(6):395-409

The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management.

Katz P; Leiter LA; Mellbin L; Rydén L
Review: EUROPEAN HEART JOURNAL. 2013;34(28):2159-2219

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Mancia G; Fagard R; Narkiewicz K; Redon J; Zanchetti A; Böhm M; Christiaens T; Cifkova R; De Backer G; Dominiczak A; Galderisi M; Grobbee DE; Jaarsma T; Kirchhof P; Kjeldsen SE; Laurent S; Manolis AJ; Nilsson PM; Ruilope LM; Schmieder RE; Sirnes PA; Sleight P; Viigimaa M; Waeber B; Zannad F; Redon J; Dominiczak A; Narkiewicz K; Nilsson PM; Burnier M; Viigimaa M; Ambrosioni E; Caufield M; Coca A; Olsen MH; Schmieder RE; Tsioufis C; van de Borne P; Zamorano JL; Achenbach S; Baumgartner H; Bax JJ; Bueno H; Dean V; Deaton C; Erol C; Fagard R; Ferrari R; Hasdai D; Hoes AW; Kirchhof P; Knuuti J; Kolh P; Lancellotti P; Linhart A; Nihoyannopoulos P; Piepoli MF; Ponikowski P; Sirnes PA; Tamargo JL; Tendera M; Torbicki A; Wijns W; Windecker S; Clement DL; Coca A; Gillebert TC; Tendera M; Rosei EA; Ambrosioni E; Anker SD; Bauersachs J; Hitij JB; Caulfield M; De Buyzere M; De Geest S; Derumeaux GA; Erdine S; Farsang C; Funck-Brentano C; Gerc V; Germano G; Gielen S; Haller H; Hoes AW; Jordan J; Kahan T; Komajda M; Lovic D; Mahrholdt H; Olsen MH; Ostergren J; Parati G; Perk J; Polonia J; Popescu BA; Reiner Z; Rydén L; Sirenko Y; Stanton A; Struijker-Boudier H; Tsioufis C; van de Borne P; Vlachopoulos C; Volpe M; Wood DA
Other: EXPERT REVIEW OF CARDIOVASCULAR THERAPY. 2012;10(9):1097-1099

Evidence for a beneficial effect of glucose-insulin-potassium in patients with acute coronary syndromes: Did the IMMEDIATE trial solve an unanswered question?

Mellbin L; Rydén L
Review: EUROPEAN HEART JOURNAL. 2012;33(13):1635-1701

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Perk J; De Backer G; Gohlke H; Graham I; Reiner Z; Verschuren M; Albus C; Benlian P; Boysen G; Cifkova R; Deaton C; Ebrahim S; Fisher M; Germano G; Hobbs R; Hoes A; Karadeniz S; Mezzani A; Prescott E; Ryden L; Scherer M; Syvänne M; Scholte op Reimer WJM; Vrints C; Wood D; Zamorano JL; Zannad F; European Association for Cardiovascular Prevention; ESC Committee for Practice Guidelines (CPG)
Review: DIABETES & VASCULAR DISEASE RESEARCH. 2012;9(3):170-176

Glucose perturbations and cardiovascular risk: challenges and opportunities.

Rydén L; Mellbin L
Review: ATHEROSCLEROSIS. 2012;223(1):1-68

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Perk J; De Backer G; Gohlke H; Graham I; Reiner Z; Verschuren WMM; Albus C; Benlian P; Boysen G; Cifkova R; Deaton C; Ebrahim S; Fisher M; Germano G; Hobbs R; Hoes A; Karadeniz S; Mezzani A; Prescott E; Ryden L; Scherer M; Syvänne M; Scholte Op Reimer WJM; Vrints C; Wood D; Zamorano JL; Zannad F; Fifth Joint Task Force of the European Society of ; European Association for Cardiovascular Prevention
Editorial comment: EUROPEAN HEART JOURNAL. 2011;32(16):1964-1967

Bringing prevention to the population: an important role for cardiologists in policy-making.

O'Kelly S; Andersen K; Capewell S; Rydén L
Letter: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2010;145(2):259-260

The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction.

Hage C; Malmberg K; Rydén L; Wallander M
Review: JOURNAL OF CARDIOVASCULAR RISK. 2010;17 Suppl 1:S9-14

Diabetes, prediabetes and cardiovascular risk.

Mellbin LG; Anselmino M; Rydén L
Editorial comment: JOURNAL OF CARDIOVASCULAR RISK. 2010;17 Suppl 1:S1

Reducing cardiovascular risk in patients with type 2 diabetes mellitus.

Nicholls SJ; Rydén L
Meeting abstract: VALUE IN HEALTH. 2009;12(7):A386

RIMONABANT IN CLINICAL PRACTICE (RICP). A SWEDISH MULTICENTER SURVEY IN PRIMARY CARE

Linder R; Birgersson OM; de Faire U; Ridderstrale M; Rossner S; Sjostrom L; Ryden L
Letter: CIRCULATION. 2009;120(9):e68

Letter by Settergren et al regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".

Settergren M; Rydén L; Pernow J
Review: CURRENT OPINION IN CARDIOLOGY. 2009;24(5):461-467

Strategies to enhance cardiovascular disease prevention in patients with diabetes.

Anselmino M; Rydén L
Editorial comment: NATURE CLINICAL PRACTICE ENDOCRINOLOGY AND METABOLISM. 2009;5(1):8-9

Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?

Rydén L; Malmberg K; Mellbin L
Review: DIABETES & VASCULAR DISEASE RESEARCH. 2008;5(4):285-290

Implications of abnormal glucose metabolism in patients with coronary artery disease.

Anselmino M; Wallander M; Norhammar A; Mellbin L; Rydén L
Letter: EUROPEAN HEART JOURNAL. 2008;29(16):2058-2059

Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it?

Garcia RG; López-Jaramillo P
Editorial comment: NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE. 2008;5(7):370-371

What are the risk factors for progression of coronary artery calcification in patients with type 2 diabetes?

Rydén L
Letter: HEART. 2008;94(7):935

Not only after myocardial infarction -: Reply

Norhammar A; Ryden L
Editorial comment: HERZ. 2008;33(3):169

Diabetes and the heart - revisited.

Rydén L; Tschöpe D; Dörr R
Review: BLOOD PRESSURE. 2008;17(5-6):250-259

The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements.

Rydén L; Waeber B; Ruilope LM; Mancia G; Volpe M; Holzgreve H; Mogensen CE; Laurent S
Letter: EUROPEAN HEART JOURNAL. 2008;29(8):1076-1077

Glucose, insulin, and coronary heart disease:: reply

Mellbin LG; Malmberg K; Norhammar A; Ryden L
Published paper: JOURNAL OF INTERNAL MEDICINE. 2007;262(2):145-156

Hyperglycaemia and cardiovascular disease.

Bartnik M; Norhammar A; Rydén L
Editorial comment: JOURNAL OF CARDIOVASCULAR RISK. 2007;14(3):355-356

The European Heart Health Charter: towards a healthier Europe.

Rydén L; Martin J; Volqvartz S
Letter: EUROPEAN HEART JOURNAL. 2007;28(11):1402

Rinnonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply

Ryden L; Standl E
Review: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2007;9(C):C3-C74

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases:: full text

Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Qiao Q; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Luis Zamorano J; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; GohIke H; Gonzalez Juanatey JR; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Letter: LANCET. 2007;369(9557):189-190

Adjudication of serious heart failure in patients from PROactive.

Rydén L; Thráinsdóttir I; Swedberg K
Review: EUROPEAN HEART JOURNAL. 2007;28(1):88-136

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

Rydén L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jönsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Qiao Q; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Zamorano JL; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; Gohlke H; Juanatey JRG; Graham I; Monteiro PF; Parhofer K; Pyörälä K; Raz I; Schernthaner G; Volpe M; Wood D; Task Force on Diabetes and Cardiovascular Diseases; European Association for the Study of Diabetes (EA
Review: SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY. 2006;18(4):326-329

Effect of insulin-glucose infusion on mortality following acute myocardial infarction in patients with diabetes: the diabetes and insulin-glucose infusion in acute myocardial infarction studies.

Malmberg K; Rydén L
Review: DIABETES & VASCULAR DISEASE RESEARCH. 2005;2(3):144-154

Management of patients with type 2 diabetes after acute coronary syndromes.

Bartnik M; Malmberg K; Rydén L
Review: PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY. 2005;28(6):573-584

Development of implantable devices for continuous ambulatory monitoring of central hemodynamic values in heart failure patients.

Bennett T; Kjellstrom B; Taepke R; Ryden L
Letter: EUROPEAN HEART JOURNAL. 2005;26(6):623-624

Oral glucose tolerance test or metabolic syndrome criteria to predict risk in patients with coronary heart disease?:: reply

Bartnik M; Rydén L
Editorial comment: HEART. 2004;90(12):1483-1484

Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.

von Bibra H; Hansen A; Dounis V; Bystedt T; Malmberg K; Rydén L
Editorial comment: JOURNAL OF CARDIOVASCULAR RISK. 2004;11(2):85-86

Promoting heart health--a European consensus.

Shelley E; Ryden L
Review: CARDIOVASCULAR THERAPEUTICS. 2004;22(3):227-250

Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.

Nordlander M; Sjöquist P-O; Ericsson H; Rydén L
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:711

Does baseline heart rate determine the effect of carvedilol on ventricular remodelling in heart failure?: Results of the CARMEN trial

Remme W; Riegger G; Rydén L; Bobbio M; Hildebrandt P; Soler-Soler J; Jaarsma W; Komajda M
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:361

Brain natriuretic peptide and N terminal pro-brain natriuretic peptide for treatment monitoring in patients with left-ventricular systolic heart failure: a substudy of the CARMEN trial

Groenning BA; Hildebrandt P; Riegger GA; Nilsson JC; Komajda M; Ryden L; Remme WJ
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:55

Tissue Doppler imaging for the early detection of myocardial dysfunction in patients with type 2 diabetes mellitus

Thrainsdottir IS; Von Bibra H; Malmberg K; Rydén L
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:357

Closure or conservative management of atrial septal defects in adults:: experiences from 25 years of follow-up of 325 patients

Rane EM; Forssell G; Ivert T; Rydén L
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:539

Impaired glucose tolerance and diabetes mellitus; very common in patients with acute coronary syndromes

Bartnik M; Malmberg K; Nilsson G; Norhammar A; Tenerz A; Ryden L
Editorial comment: LANCET. 2002;360(9348):1866-1869

The need for resources for clinical research: the European Society of Cardiology calls for European, international collaboration.

Bassand J-P; Martin J; Rydén L; Simoons M; European Society of Cardiology
Review: CARDIOVASCULAR RESEARCH. 2002;55(1):25-37

Pharmacological possibilities for protection against myocardial reperfusion injury.

Wang Q-D; Pernow J; Sjöquist P-O; Rydén L
Other: PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY. 2002;25(4):521

Arne!Larsson 1915-2001 -: Obituary

Rydén L; Schüller H; Larsson B
Editorial comment: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2001;3(L):L1-L2

Hypertrophic cardiomyopathy:: from molecular and genetic mechanisms to clinical management

Ferrari R; Rydén L
Editorial comment: EUROPEAN HEART JOURNAL. 2001;22(20):1839-1843

Partnership in cardiovascular medicine. A key to success not only for professional organizations.

Rydén L; Simoons ML; Bassand JP
Published paper: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 2001;498:279-284

Insulin treatment post myocardial infarction: the DIGAMI study.

Malmberg K; Norhammar A; Rydén L; DIGAAMI study
Published paper: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2000;36(5 Suppl 1):S418-S420

Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis.

Pernow J; Böhm F; Johansson BL; Hedin U; Rydén L
Editorial comment: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2000;36(3):957-958

Joint efforts across national boundaries between professional organizations in cardiovascular medicine: one way into the future.

Beller GA; Rydén L
Editorial comment: HEART. 2000;84 Suppl 1(Suppl 1):i1

Renin-angiotensin system modulating treatments in the management of cardiovascular disease.

Rydén L
Letter: LANCET. 2000;355(9198):149-150

European role in global cardiology.

Rydén L; Breithardt G; Poole-Wilson P
Published paper: CLINICAL RESEARCH IN CARDIOLOGY. 2000;89 Suppl 1:86-96

[Contrast echocardiography].

von Bibra H; Bone D; Voigt JU; Niklasson U; Wranne B; Rydén L
Published paper: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2000;2(I):L3-L7

Benefits of ACE inhibitors:: what remains to be proven?

Rydén L; Malmberg K
Editorial comment: EUROPEAN HEART JOURNAL. 1999;20(18):1287-1289

ACE inhibitors or AT(1) receptor blockers in heart failure?

Rydén L
Editorial comment: EUROPEAN HEART JOURNAL. 1999;20(17):1219-1221

The careers of female cardiologists.

Rydén L; Schenck-Gustafsson K
Editorial comment: EUROPEAN HEART JOURNAL. 1999;20(16):1149-1151

Guidelines: making the headlines or confined to the sidelines?

Bassand JP; Rydén L
Review: EUROPEAN HEART JOURNAL. 1999;20(12):867-871

Treatment of congestive heart failure. Has the time come for decreased complexity?

Rydén L; Remme WJ
Meeting abstract: ATHEROSCLEROSIS. 1999;144:144

Future perspectives on the management of angina pectoris

Rydén L
Published paper: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, SUPPLEMENT. 1999;100:17-18

Results of the ATLAS study.

Rydén L
Editorial comment: EUROPEAN HEART JOURNAL. 1999;20(6):403-405

Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist.

Wikström G; Malmberg K; Rydén L
Published paper: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 1999;10 Suppl 11:S137-S142

Effects of the angiotensin AT1 receptor blocker candesartan on myocardial ischemic/reperfusion injury.

Shimizu M; Sjöquist PO; Wang QD; Rydén L
Published paper: EUROPEAN HEART JOURNAL SUPPLEMENTS. 1999;1(Q):Q3-Q6

A review of evidence of benefits from ACE inhibitors in heart failure compared with AT₁ receptor blockers and other therapies

Rydén L
Editorial comment: EUROPEAN HEART JOURNAL SUPPLEMENTS. 1999;1(Q):Q1-Q2

Evidence-based management of heart failure:: ACE inhibitors and AT₁ receptor blockers -: Proceedings of a roundtable meeting held in New Orleans, USA, 6 March 1999 -: Foreword

Rydén L; Hobbs FDR
Editorial comment: EUROPEAN HEART JOURNAL. 1998;19(9):1269-1272

Calcium antagonists, appropriate therapy for diabetic patients with hypertension?

Malmberg K; Rydén L; Wedel H
Editorial comment: EUROPEAN HEART JOURNAL. 1997;18(10):1523-1525

Distribution of knowledge.

Rydén L; Poole-Wilson P; Breithardt G
Published paper: AMERICAN JOURNAL OF CARDIOLOGY. 1997;80(5A):64E-67E

The way ahead in the management of unstable coronary artery disease.

Rydén L; Hamsten A
Review: LAKARTIDNINGEN. 1997;94(25):2369-2372

[Care of heart failure may be better].

Rydén L
Editorial comment: EUROPEAN HEART JOURNAL. 1997;18(3):360-361

Restoration of atrial function after the maze procedure.

Darpö B; Ryden L
Corrigendum: CARDIOVASCULAR RESEARCH. 1997;36(3):460

Mortality prediction in diabetic patients with myocardial infarction:: experiences from the DIGAMI study (vol 34, pg 248, 1997)

Malmberg K; Ryden L; Hamsten A; Herlitz J; Waldenström A; Wedel H
Review: LAKARTIDNINGEN. 1996;93(39):3349-3350

[Surgical treatment of atrial septal defect. Good therapeutic alternative even for the elderly].

Forssell G; Rydén L; Rane EM
Editorial comment: EUROPEAN HEART JOURNAL. 1996;17(1):1-3

Calcium channel blockers or beta receptor antagonists for patients with ischaemic heart disease. What is the best choice?

Rydén L; Malmberg K
Editorial comment: PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY. 1995;18(7):1341-1345

Pacing in dilated cardiomyopathy.

Linde C; Rydén L
Visa fler

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI